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ACROLEIN SUPPRESSES MOBILIZATION OF ENDOTHELIAL PROGENITOR 
CELLS 
Laura Anne Wheat Nissley 
December 16th 2011 
Acrolein is a common pollutant present in ambient air, automobile 
exhaust, and tobacco smoke. Previous studies show that exposure to acrolein 
increases cardiovascular disease risk. To determine whether acrolein affect 
cardiovascular regeneration, we investigated the cardiovascular effects of 
inhaled acrolein. Adult male CS7BLl6 mice were exposed to room air or acrolein 
(O.S, 1 or S ppm) for and the endothelial progenitor cells (EPC) level in peripheral 
blood (PB) was measured by flow cytometry. To examine the proliferative 
capacity of EPCs, bone marrow cells (BMCs) were cultured on fibronectin-coated 
slides. Brief exposure to acrolein (S ppm, 6h) or 4 day (1 ppm) exposure led to a 
42% decrease in PB Flk+/Sca+ cells. BMCs isolated from mice exposed to 
acrolein for 1 d (S ppm) or 4d (1 ppm) formed more colonies than BMCs of air-
exposed mice. Combined VEGF-A (100 I-Ig/kg, ip, 4d) and AMD3100 (S mg/kg; 
ip, last day only) treatment increased PB EPCs cells in air-exposed mice but not 
in acrolein-exposed mice (1 ppm, 4d). These data indicate that circulating EPCs 
v 
are a sensitive target of airborne pollutants and that acrolein at 
concentrations encountered in tobacco smoke suppresses EPC levels in the 
blood but it increases the proliferative capacity of EPCs in the bone marrow. My 
thesis is that EPCs are sensitive targets for environmental insults, such as 
acrolein, thus increasing the risk of developing cardiovascular disease and 
endothelial dysfunction. Studies here show that the effects of acrolein on EPC 
after exposure by inhalation (Aim 1), the environmental pollutant acrolein, 
prevents mobilization of EPCs by cytokine stimulation (Aim 2), evaluated 
perfusion recovery of hindlimb ischemia after exposure to acrolein inhalation 
(Aim 3). 
The results of these studies support the hypothesis that exposure to 
environmental pollutant acrolein prevents EPC mobilization. 
VI 
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ENVIRONMENTAL POLLUTION AND CIGARETTE SMOKE 
The United States and other industrialized countries face an increasing 
amount of air pollution and related health concerns. The World Health 
Organization (WHO) data base has estimated that 1.5 billion people in the world 
are exposed to dangerously high levels of pollution on a daily basis 1. WHO also 
estimates 3 million deaths are attributed to outdoor air pollution and 1.6 million 
deaths are attributed to indoor-air pOllution2. The earth's atmosphere itself is a 
complex mixture of gases, changing in composition with each atmospheric layer. 
However, when defining environmental pollution the two layers of concern are 
the troposphere and stratosphere. The troposphere is the lowest portion of the 
earth's atmosphere, it contains approximately 80% of the total atmosphere mass 
and 99% of its water vapor and aerosols and the ozone layer is located within the 
stratosphere. 
When defining pollution Webster dictionary simply states, "pollution 
is the introduction of contaminants into a natural environment that causes 
instability, disorder, harm or discomfort to the ecosystem i.e. physical systems 
or living organisms". The EPA in conjunction with the Commission for 
Environmental Cooperation estimates each year the United States alone spews 3 
million tons of toxic chemicals into the air, water and land 3. There are also naturally 
occurring sources of pollution such as volcanic eruptions, pollen, mold, sulfur release 
from oceans and forest fires 4-8. For the most part, pollution is man-made, has many 
sources and has escalated since the dawn of the industrial revolution. However, 
pollution isn't just a plague of modern society even in prehistoric time man was 
exposed to pollution. Scientists have found signs of indoor pollution on cave walls in 
the form of soot that resulted from building fires for heating and cooking with no or little 
ventilation 9. Modern pollution can still be attributed to wood burning but also the 
combustion of any petroleum product or byproduct, smelting, agriculture, cooking, coal 
burning, production of plastic, foam, energy, and nuclear power; the list goes on 10-14. 
Historically, pollution has been associated with severe or even life threatening health 
conditions. Cigarette smoke and second hand cigarette smoke exposure is a well 
publicized and published pollutant that is directly linked to the development of cancer; 
but can cause asthma, emphysema, decreased birth weight, increased risk for heart 
disease, stroke, coronary heart disease, and overall increased morbidity 15-19. 
The EPA has classified 5 major pollutants; ozone (03), carbon monoxide 
(CO), nitrogen oxides (NO), particulate matter (PM), sulfur dioxide (S02), and lead. 
Each pollutant is produced from a number of sources and can have varying health 
effects. Ozone is a colorless gas that constitutes photochemical smog at the earth's 
surface. Ozone is formed in the lower troposphere as a result of chemical reactions 
between oxygen, volatile organic compounds and nitrogen oxides in the presence of 
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sunlight 20. Ozone has been associated with significant health problems including 
impaired lung function, chest pain, cough and lung inflammation 21,22. Carbon 
monoxide is an odorless colorless gas emitted from the exhaust of vehicles and other 
kinds of engines where there is incomplete fossil fuel combustion 23. Carbon monoxide 
reduces the ability of blood to deliver oxygen to vital tissues, effecting primarily the 
cardiovascular and nervous systems 24-26. Nitrogen dioxide is a light brown gas that 
results from the burning of fossil fuels in utilities, cars, and trucks 23. Nitrogen dioxide is 
the major cause of smog, acid rain and at high levels can be harmful to not only 
humans but vegetation as well 27,28. Particulate matter (PM) can be solid or liquid 
droplets from smoke, dust, fly ash and condensed vapors. Particulate matter is 
produced from industrial processes, smelters, automobiles, burning industrial fuels, 
wood smoke, and dust from unpaved roads29. These microscopic particles can affect 
breathing, respiratory tract health, increased respiratory disease, lung damage and 
linked to increased morbidity 30,31. Sulfur dioxide is a colorless odorless gas emitted 
largely from industrial, institutional, utility, and apartment-house furnaces and boilers, 
as well as smelters, paper mills, petroleum refineries, and chemical plants32, 33. Sulfur 
dioxide is one of the major pollutants that causes smog and can affect susceptible 
individuals like asthmatics 23,34. Lead and lead compounds can adversely affect human 
health by either ingestion or direct inhalation of contaminated soil, dust, paint 35. 
Exposure to lead can affect mental development, kidney function, and blood chemistry 
36, 37 
History has shown that exposure to increased amounts of pollution can be 
devastating. There have been several acute incidences displaying the effect that 
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pollution has on human health, and mortality. Several cities and towns have 
encountered these events first hand. Notable pollution related deaths have occurred in 
the past due to weather inversions in conjunction with increased industrial activity in 
low lying areas. One of the earliest recorded cases was in the Meuse Valley in 
Belgium, December 1930, killing 60 and sickening another 6,000 people. Deaths were 
attributed to "episodes of severe pulmonary attacks". Investigators pOinted to the 
probability that sulfur dioxide (S02) or oxidation products of that compound from factory 
smoke along with unusual weather patterns were the cause 38. In 1948 over a span of 2 
days the small town of Donora, Pennsylvania also suffered severe casualties. Thick 
smog trapped from an iron smelting plant combined with weather inversion, was 
responsible for killing 20 people and sickening 6,000 more 39. Years later in 1952, 
12,000 people died and 100,000 were sickened by pollution and stalled weather 
patterns in greater downtown London, England. Thousands of tons of black soot, tar 
particles, and sulfur dioxide had accumulated in the air due to the heavy coal 
combustion from factories along the river Thames. Estimates of PM10 concentrations 
during December, 1952, range between 3,000 and 14,OOOIJ9/m3 with the high range 
being approximately 50 times higher than normal levels 40,41. After this incident it 
became evident the Donora disaster was just the beginning and led the United States 
Congress to pass the first air pollution policy in 1955, the Air Pollution Clean Act. This 
policy was later followed by the formation and implementation of the EPA in 1970 by 
President Richard Nixon 42,43. 
Depending on the geographic location, population density, and level of 
industrialization; pollution can vary in concentration and composition. Hong Kong, 
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China has a population of 7.2 million and a population density of 16,576 people/mile2 . 
Hong Kong is highly industrialized with little emission control policies enforced on 
industry. Therefore, it is not surprising that Hong Kong is one of the most polluted cities 
in the world 44. The major 5 recognized pollutants vary in concentration; S02 350 jJg/m3, 
PM 1BO jJg/m3, NO 150 jJg/m3, CO 10,000 jJg/m3, 0 3 24 jJg/m3 45,46. Compared to Hong 
Kong, Los Angeles, California has drastically different levels of pollution. Los Angeles 
has a population of 3.B million and density of 7,544 people/mile2,California boasts 
extremely strict emission control laws and has a different industrial base, which 
accounts for the vast difference when compared to Hong Kong. The major 5 pollutants 
in ambient Los Angeles air; S02 0.43 jJg/m3, PM 39 jJg/m3, NO 14.3 jJg/m3, CO 304 
jJg/m3, 0 3 13 jJg/m3 47,48. When levels of these pollutants reach high enough levels, 
they can be hazardous or even deadly upon exposure and can cause serious health 
effects with long term repeated exposure. The Occupational Safety and Health 
Administration (OSHA) has compiled permissible exposure limits (PELs) for hundreds 
of pollutants. Studies have found there are no real "safe" or acceptable exposure 
concentrations of troposphere or ground-level ozone exposure. Overtime, exposure to 
ozone will have negative health related effects, but OSHA ozone PELs is 0.075ppmlBhr 
day. Sulfur dioxide PELs are not to exceed 140pbb in a 24hr period. Particulate matter 
PELs are not to exceed (PM2.5) 35jJg/m3 per 24 hour period, (PM10)150jJg/m3 per 24 
hour period. Acceptable nitric oxide exposure levels have become more stringent, 
individuals are not to exceed 1 OOppb/hr of exposure. Carbon dioxide standards allow 
individual exposures to reach 9ppmlBhr day. OSHA has found these safety standard 
exposure levels to have no long-term health effects. However, data now show for every 
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10jJgI m3 of city specific particulate matter2.5 the mortality ratio rate (RR) is 1.13, 
demonstrating an inverse correlation between pollution levels and mortality 49,50. 
Environmental tobacco smoke (ETS) is a pollutant associated with 
severe health consequences. Smoke from cigarettes is a complex mixture of 
4,000 different chemicals; 50 known carcinogens; 200 known poisons. ETS is 
made up of a combination of side stream and mainstream cigarette smoke. Side 
stream cigarette smoke is smoke coming off the end of a smoldering cigarette. 
Mainstream smoke is considered active smoking, the combination of inhaling and 
exhaling after taking a puff on a lit cigarette. The frequency of puffs, duration and 
volume all contribute to the make-up of mainstream smoke51 , 52. Each of the 
chemicals in cigarettes varies depending on brand and country of origin (Table 1) 
53-57. Studies have shown that exposure levels increase significantly from 
mainstream smoke to side stream smoke, particulate matter significantly 
increases by 5 fold like58. Even though combustable tobacco products are full of 
numerous chemical aldehydes are highly reactant and abundant within cigarette 
smoke (Table 2). Even though acrolein is not necessarily the most prevalent of 
the aldehydes it is one of the most reactive. 
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Table 1: Cigarette chemical content (one burned cigarette) 53-57 
Brand Acrolein CO Nicotine Tar Country or 
origin 
Merit 631-1g 9 0.8 mg 10 mg USA 
Marlboro 1551-1g 10 1.8 mg 12 mg USA 
Camel 1491-1g 16 1.1 mg 15 mg USA 
Sakura 350 l-lg 18 2.0 mg 26 mg Japan 
Table 2: Aldehyde content cigarettes (US Dept of Health and Service) 
Aldehyde Amount per cigarette 




Exposure to ETS whether it is from actively smoking or from second hand 
exposure is a major cardiovascular risk factor 59,60. The WHO estimate over 26.5 
% of males and 22.1 % or females in the world actively smoke; while 43 % of the 
world's children are exposed to second hand smoke 61. Every year 5 million 
active smokers die, while 600,000 people exposed to second hand smoke also 
succumb to smoke related illnesses 62. Cigarette smoke is associated with 
endothelial dysfunction, decreased angiogenesis, increased arteriosclerosis and 
various other cardiovascular diseases 18,63,64. Nevertheless, the specific 
chemicals in the tobacco smoke that cause toxicity have not been identified and 
the mechanisms underlying the cardiovascular toxicity of tobacco smoke remains 
unclear. The main questions remain what chemical(s) constituents, 
mechanism(s) and susceptibility factors associated with ETS and environmental 




Acrolein is an unsaturated aldehyde also known as acrylaldehyde, acrylic 
aldehyde, allyl aldehyde, ethylene aldehyde, 2-propenal, and prop-2-en-1-al. 







Molecular weight: 56.06 gtmol 
Vapor pressure: 274 mmHg 
Conversion factor: 1 ppm = 2.3 mgt m3; 1 mgt m3 = 0.44 ppm 
Acrolein is used in industry for the production of plastics, rubber and as an 
intermediate in the production of acrylic acid. Acrolein is also used as an 
herbicide, aquacide, slimicide; on farms, in drainage ditches and in paper 
production. Acrolein is also present in varying concentrations as a result of 
combustion of organic material (Table 3) 65-67. Acrolein is highly water soluble 
and possesses low vaporizing pressure making acrolein a highly mobile 
substance. In ambient air acrolein ecxist solely in a vapor-phase, and exposure 
occurs primarily through atmospheric contact. For long-term outdoor pollution 
studies, government agencies use TO-11A method (active sampling with 2-4 
dinitrophynlhydrazine [DNPH] coated solid sorbents). This particular method 
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samples air downstream of KI oxidant scrubbers which then pass on to silica gel 
cartridges coated with DNPH, DNHP derivatives are analyzed by liquid 
chromatography (LC) with detection by diode-array, UV-visible spectroscopy. 
The DNHP method is unstable with humidity, temperature and ozone level 
fluctuation. This method is used primarily on the west coast and mid-west 
regions. The most recent and highly stable system for collecting airborne 
aldehyde and ketone data is the modified passive aldehyde and ketone sampler 
(PAKs). PAKs method for collection effeciencys is -100% for most saturated 
carbonyls, and 99±S% for acrolein even with humidity fluctuations from 30-90%. 
(Table 4). 
10 
Table 3: Sources and level of acrolein emissions 
Source Amount 
Gas engine exhaust 0.05-27.7 mg/m~ 
Diesel engine exhaust 0.12-0.21 mg/m3 
Smoky indoor environment 2.3-275 IJg/m3 
Residential wood stoves 0.7-6.0 IJg/m 3 
Main stream cigarette smoke (exhaled 1 0-140 IJg/m~ 
smoke) 
Side stream cigarette smoke 100-1700 IJg/m 3 
(smoldering ash) 
Total industrial air emissions 208,1081bs 
Fires (Boston, USA) 6.9 mg/m~ 
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Table 4: Methods for acrolein sampling and testing.a.b 
Sample Sample preparation Assay Limit of Reference 
matrix procedure detection 
Air Adsorb on sorbent coated with 2- GC/NSD 2 jJg/sample US OSHA, 
(hydroxymethyl)piperidine on (6.1 jJg/m3 ) 1989; Eller, 
XAD-2; desorb with toluene; 1994 
analyse for oxazolidine derivative 
Draw air through midget impinger Reversed- NR US EPA, 
containing acidified DNPH and phase 1988 
isooctane; extract DNPH HPLC/UV 
derivative with 
hexane:dichloromethane (70:30) 
solution; evaporate to dryness; 
dissolve in methanol 
Draw air through bubblers in Colorimetry 22.9 jJglmj Feldstein 
series containing 4- (10 ppb)C et aI., 
hexylresorcinol in an alcoholic 1989a 
trichloroacetic acid solvent 
medium with mercuric chloride 
Draw air through midget impinger Colorimetry 22.9 jJg/m' Feldstein 
containing 1 % sodium bisulfite; (10 ppb) et aI., 
react with 4-hexylresorcinol in an 1989b 
alcoholic trichloroacetic acid 
solvent medium with mercuric 
chloride 
Moist air Collect in DNPH-impregnated HPLC/UV 0.3 Vainiotalo 
adsorbent tubes (with calcium jJg/sample & 
chloride tubes); extract with (0.01 Matveinen, 
acetonitrile mg/m3) 1992 
Exhaust Derivatize with O-benzyl- GC/ECD NR Nishikawa 
gas hydroxylamine to O-benzyloxime; et aI., 
brominate with sulfuric acid, 1987a 
potassium bromate, and 
potassium bromide; reduce with 
sodium thiosulfate; extract with 
diethyl ether 
Aqueou Derivatize with 0-(2,3,4,5,6- MIMS/EIM 10 jJg/litre Choudhury 
s pentafluorobenzyl)hydroxylamine S (10 ppb) et aI., 1992 
solution 
Rainwat Derivatize with O-methoxylamine GC/ECD 0.4 jJg/I itre Nishikawa 
er to O-methyloxime; brominate with et aI., 
sulfuric acid, potaSSium bromate, 1987b 
and potassium bromide; reduce 
with sodium thiosulfate; elute with 
diethyl ether 
Liquid Purge (inert gas); trap in suitable GC/FID 0.7 jJg/litreO US EPA, 
and adsorbent material; desorb as 1986 
solid vapour onto packed gas 






Biologic Oerivatize with ONPH; extract HPLC/UV 1 ng Boor & 
al with chloroform, hydrochloric Ansari, 
samples acid; dry with nitrogen; dissolve in 1986 
methanol 
From IARC (1995). 
Abbreviations used: ON PH = 2,4-dinitrophenylhydrazine; ECO = electron capture 
detection; FlO = flame ionization detection; GC = gas chromatography; HPLC/UV = 
high-performance liquid chromatography/ultraviolet detection; MIMS/EIMS = 
membrane introduction mass spectrometry/electron impact mass spectrometry; 
MS = mass spectrometry; NR = not reported; NSO = nitrogen selective detection. 
Note that 1 ppb = 1 x 10-9. 
Practical quantification limits for other matrices: 7 jJgllitre for groundwater; 7 jJg/kg for 
low-level soil samples; 350 jJgllitre for water-miscible liquid waste samples; 875jJg/kg 
for high-level soil and sludge samples; 875jJgllitre for non-water-miscible waste samples. 
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The EPA reported mean ambient concentrations of acrolein to be 14.3I-1g/ m3 (6 
ppb) (Table 3) 65-67. 
Not only can we breath in acrolein we can also ingest acrolein, through heating of 
carbohydrate-containing foods which results in the formation of reactive 
carbohydrate intermediates that can undergo carbon-carbon cleavage and 
ultimately produce acrolein68. Acrolein is a highly reactive electrophile due to the 
polarization of the double bond by the aldehyde group. In the body acrolein 
reacts readily with protein nucleophiles, non-protein sulfhydryl groups, or primary 
and secondary amines found in nucleic acids. Acrolein is endogenously 
produced as a by-product of lipid peroxidation and possible mediator in several 
human diseases, as reviewed by Uchida et at .,69, 70 Acrolein conjugates readily 
and rapidly with sulfhydryl groups and is essentially irreversible. This reaction 
leads to the formation of thiazolidine derivatives and a decrease in glutathione 
(GSH) stores without an increase in oxidized GSH (GSSG). This pathway results 
in an acrolein-GSH adduct which is further metabolized by both mitochondrial 
and cytosolic aldehyde and alcohol dehydrogenase. Ultimately acrolein is 
excreted in urine as mercapturic acid derivatives, or remains as protein-acrolein 
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Figure 1 metabolism of acrolein Intermediary metabolism can form Acrylic acid 
or Glycidaldehyde from acrolein, acrolein can also be excreated in the urine as 
mercapturic acid derivatives goes through several 
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It has been previously shown that administration of radioactive acrolein (0.82 
mg/kg) to lactating goats, incorporation of the radioactivity appeared to follow 
incorporation of metabolites into normal biosynthetic pathways of both mother 
and nursing kid 72. 
Acute exposure to acrolein at levels as low as 0.99_ppm for 5 min 
causes severe eye and nose irritation in humans 73,74. Lyons et a/., 75 showed in 
a multi-species study containing fifteen Sprague-Dawley rats (male), seven to 
eight Princeton or Hartley guinea pigs (male), two pure bred beagle dogs (male); 
and nine squirrel monkeys (male). All species were exposed to acrolein, 8 hr/day, 
5 days/week, for 6 weeks at concentrations of either 0.7ppm or 3.7ppm. No 
deaths were reported in the 0.7ppm group, histopathology of the lungs showed 
significantly increased inflammation in all species, however inflammation was 
found to be significantly more chronic in the lungs of more complex organisms; 
beagles and monkeys. In the 3.7ppm group, two monkeys died within two weeks 
after onset of exposure. All species exhibited extensive mucosal gland irritation 
within the first week which continued throughout the remainder of the study. In 
histological sections non-specific inflammatory changes were noted in the lungs, 
liver, and kidney of all species inflammatory changes within the lung were seen in 
the bronchi rather than the bronchioles. All study groups were found to be 
significantly different from that of control groups. Data supports acroleins ability 
to cause extreme tissue inflammation and damage not only in the lungs but can 
travel to various organs throughout the body and inflammation severity varies 
17 
from species to species. The more complex organisms seemed to be more 
susceptible to inflammation caused by acrolein inhalations. 
Acrolein is classified as an environmental toxicant, the defined OSHA 
permissible exposure limit is 0.1 ppm per 8 hi d (time weighted average;TWA) or 
0.3ppm for 15 min. short term exposure (TWA). Both are near or above acrolein's 
odor threshold of 0.2ppm.Acrolein can cause disruptions in sulfahydryl groups 
that are critical for chemical reactions within living cells, leading to disruption of 
intermediate metabOlism, inhibition of cell growth or division, and cell death 76. 
Acrolein is a known constituent of environmental tobacco smoke (ETS); ETS 
promotes arteriosclerosis and endothelial dysfunction by inducing 
proinflammatory stimuli. The link between cigarette smoke and cardiovascular 
disease is poorly understood, however due to the abundance, reactivity, and 
proinflammatory nature, acrolein is a likely candidate 77. There is a need to 
further understand acroleins possible role in cardiovascular disease and the link 
between cigarette smoke. The CDC reports people that smokers are 2-4 times 
more likely to develop coronary heart disease compared to non-smokers. 
Endothelial Progenitor Cells 
Prior to 1997, angiogenesis was thought to occur only in a neonatal state, as 
mesodermal cells differentiated into angioblasts, ultimately giving rise to 
endothelial cells, the process of neovascularization. However, in 1997 Asahara 
and colleagues revolutionized this dogma with the discovery of CD34 + cell subset 
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that possessed an endothelial phenotype. The endothelial like cells were sorted 
from human blood by magnetic beads and autologous transplants showed these 
cells had the ability to incorporated into sites of active angiogenesis and were 
beneficial in wound healing, they coined these cells Endothelial Progenitor Cells 
(EPCs) 78. 
Definition: 
EPCs originate from the bone marrow (8M) and are present in either a quiescent 
state in the non-vascular niche of the 8M or a proliferative state in the vascular 
niche from which they are mobilized79, 80. EPCs can be defined by numerous 
markers in varying combinations, the most accepted is a combination of a stem 
cell marker along with an endothelial lineage marker. In the initial paper Asahara 
et. aI., human blood was drawn, sorted by magnetic bead for CD34+ and Flk-1+ 
cells, then stained for CD45, CD34, CD31, Flk-1, TIE-2 and E-Selectin78 . There 
are several markers commonly used to discern EPCs from other cells present 
within the body (Table 5) 81,82. 
19 
Table 5: Commonly used EPC markers and definition 
Marker Definition 
Vascular Endothelial Growth Factor Endothelial marker, surface receptor 
Receptor 2+ for VEGF (mouse) 
(VEGFR2, KDR, Flk-1) 
von Willibrand factor (vWft Endothelial marker, cell surface 
marker bind to Factor VIII, important 
for platelet adhesion to wound sites 
(mouse) 
CD34+ Hematopoetic stem cell lineage 
marker, important for cell-cell 
adhesion (human) 
Lin- Cocktail of antibodies used to 
determine cellular lineage (human) 
CD4S-1o,m Surface marker on hematopoetic 
cells, protein tyrosine phosphatase 
(mouse) 
CD133+ Also known as Prominin, cell surface 
marker of unknown function (mouse) 
Lectin+ Cell surface sugar binding protein 
(mouse) 
Sca-1+ Stem cells marker-1, glycosyl 
phosphatidylinositol-anchored cell 
surface protein (mouse) 
C-kit+ Cytokine receptor, binds to stem cell 
factor 
Tie-2+ Endothelial specific, identified as 
Angiopoietin I receptor (mouse) 
CXCR4+ CXC chemokine receptor, bind SDF-
1Jmousel 
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EPCs are evaluated by surface markers and angiogenic ability when seeded on 
Mitrigel®. Angiogenic ability of these cells allow for increased repair of damaged 
vasculature and improves over all vascular health. Other endothelial properties 
have been evaluated on EPCs as well such as, NO production which is very 
important for vasodilation and further EPC homing to sites of injury. It has been 
shown circulating endothelial progenitor cells account for only 0.01 % of 
circulating cells. However, three hours after hypoxic injury, circulating EPCs are 
visibly increased, and by 24 hours they account for 12 % of Circulating cells 83 . 
Mobilization: 
Found within red bone marrow is a heterogeneous population of cells that make 
up the stem cell niche, consisting of fibroblasts, osteoclasts, hematopoietic and 
endothelial cells. The bone marrow stromal cells that line the inside 
microenvironment of the bone marrow are responsible for providing extrinsic 
signals that maintain the stem cell niche and regulate the repopulation of stem 
cells 81,84. While attached to the stromal cells, stem cells are maintained in the Go 
phase of the cell cycle, which is the quiescent non-proliferative phase. 
Endothelial progenitor cell mobilization from the bone marrow occurs when 
cytokines interact between the bone marrow stromal cells and stem cells. This 
allows stem cells to disengage the bone marrow and pass into the blood stream. 
Respectively, during hypoxic injury, the Hypoxia Inducible Factor 1-0 (HIF1-0) 
protein levels increase and cause up regulation of VEGF levels. Bone marrow 
stromal cells can bind to VEGF and increase production of nitric oxide (NO), NO 
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can then increase active-MMP-9 levels. MMP-9 is responsible for cleaving 
membrane bound kit ligand (mKitl), and thus, increasing the bioavailability of 
soluble kit ligand (sKitl). After levels of sKitl increase attached endothelial 
progenitor cells bind sKit and are pushed from a quiescent state into a 
proliferative state. Studies have concluded EPCs follow SDF-1/CXCR4 axis and 
gradients within the circulation (Scheme 1) 81,84-87. 
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Stromal Derived Factor 1 (SDF-1) protein is crucial for homing and recruitment of 
circulating EPC to sites of injury. SDF-1 has chemotactic activity that controls 
adult stem cell trafficking and is the ligand for G-protien coupled receptor 
CXCR488. EPCs possess CXCR4 receptors and it has been shown local 
administration of SDF-1 at the sites of injury increases therapeutic 
neovascularization 89. With injury to the endothelium VEGF levels steadily 
increase along with numerous other cytokines and chemokines. Various stimuli 
promote mobilization and recruitment of EPCs to sites of injury 90. Once 
circulating EPCs come into contact with the appropriate recruitment stimulus, 
surface adhesion factors are thought to be upregulated and help with cell 
recruitment and cell adhesion (Table 6) 90-97. 
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Table 6: EPC homing factors 
Chemokinel receptor Cell type and markers Animal model (species) 
and integrins 
SDF-1/ CXCR4 EPC, CD34+ Hind limb ischemia 
(Murine) 
IL-8 ICXCR2 or CXCR 1 CD34+ Myocardial infarction 
(Murine) 
HMGB-1 EPC Myocardial infarction 
(Murine) 
J32-integrin EPC Myocardial infarction, 
Hind limb ischemia 
(Murine) 





EPC transmigration is similar to leukocyte rolling and transmigration. In Vitro 
studies have lead to evidence suggesting once the EPC has made contact with 
or near the injured tissue, low affinity contacts are made between selectins 
present on the cell surface and the vascular wall, much like the process seen 
with leukocyte rolling98. The integrin, E-selectin, is important to not only homing 
but actually regulating the bone marrow-derived EPC recruitment to sites of 
injury. After cell rOlling, further adhesion occurs through ~2-integrins99, 100. For 
firm adhesion a4~1 integrins and LFA-1 increase adhesiveness via their 
respective ligands, VCAM-1 and I-CAM-1. After rolling and firm adhesion, EPCs 
must transmigrate, however, little is known about the true mechanism behind this 
process. It is postulated that PECAM-1 and CD99 playa role in transmigration of 
EPCs (Scheme 2)101. 
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After activation and mobilization into the circulation, EPCs start maturing and 
eventually loose stem cell markers and characteristics while simultaneously 
acquiring more mature endothelial cell characteristics 102. In previous studies it 
has been shown phospho-Akt is induced in the ischemic muscle by cytokines 
such as VEGF and SDF-1, which are secreted by skeletal muscle cells, stromal 
cells, and endothelial cells in response to ischemia. In particular, the 
phosphorylation of Akt in endothelial cells leads to entrapment of systemically 
administered ex vivo-expanded EPCs into the ischemic muscle through various 
kinds of mechanisms, overexpression of ICAM-1 on endothelial cells (ECs) and 
the increased incorporation and transendothelial migration of EPCs 103. In order to 
study actual incorporation, EPCs were isolated and tagged with diacyl-LDL then 
injected into nude mice. Histology sections were taken of ischemic muscle and 
56 ±4.7 % of the vessels had EPC incorporation out of the 16 section evaluated 
(1 OX field) 103. While still other studies using the same approach show only 0.01 % 
of EPCs injected going to the site of injury and actively participate in 
angiogenesis 104. Various studies report different incorporation numbers for EPCs 
at the sites of injury, this could be accounted for by the methods used and the 
analysis of data. There is are small amounts of EPCs in the circulation even after 
ischemic injury and so far histology and rudimentary counting has been the main 
published method, a lot could be missed or over counted by this approach just 
due to human error or bias. 
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When incorporated into the site of injury, EPCs act in a paracrine 
fashion releasing growth factors such as VEGF and stimulating release of NO, 
thus stimulating the release of growth factors from surrounding adult endothelial 
cells. The growth factors released recruit more EPC to the site of injury and 
other pro-angiogenic cells such as macrophages. The immature EPCs soon fully 
differentiate into mature endothelial cells, after exposure to growth factors such 
as VEGF, SDF-1, IGF-1, and HGF in the surrounding environment 91, 105-108. 
Non-Bone Marrow, Endothelial Progenitor Cell Niches 
EPC can also be found in resident tissue niches outside of the bone marrow. 
Stem cell niches provide a balance between quiescence and activity of the stem 
cell by protecting them from differentiation stimuli, apoptotic stimuli, and other 
stimuli that could challenge stem cell reserves. A stem cell niche is defined by 
functional dimensions and anatomical dimensions which specifically enable stem 
cells to asymmetrically reproduce and allow for self renewal 109-111. Stem cells 
within a niche are embedded in a 3-D extra cellular matrix (ECM). The ECM can 
be divided into two groups, structural proteins and proteoglycans (PGs), including 
glycosaminoglycans (GAGs), which are primarily responsible for regulatory 
processes in disease and development. The ECM of the stem cell niche consists 
mainly of basement membrane components, such as collagens, laminins, 
fibronectin, and GAGs. Integrins connect the ECM niche to the internal 
cytoskeleton of the stem and progenitor cells and they transmit external signals 
directly to the stem cells. When mechanical force is applied to the ECM, this 
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influences the integrins and impacts stem cell fate by activation of various 
signaling pathways. Within each niche, some ECM proteins have specialized 
functions restricted to distinct stem cell niches 112. For example, 13-1 integrins are 
predominately expressed within epidermal stem cell niches while tenascin c and 
osteopontin are specifically present in hematopoietic stem cell niches. Some 
investigators have suggested that bone marrow is the only source of 
stem/progenitor cells, however when the body depletes the bone marrow stem 
cells, non-bone marrow stem cell niches are called upon and playa vital role and 
help repair damaged tissues 113. Non-bone marrow niches are found throughout 
the body some are better documented and studied than others. It is thought that 
niches are formed during embryogenesis and stem cell migrations during fetal 
tissue development and are actually maintained into adulthood 114,115. 
The spleen contains two distinct areas known as the red and white pulp, 
the red pulp contains macrophages that filter out debris and dead cells from the 
circulation. The white pulp or "lymphoid compartment" synthesizes antibodies 
against invading pathogens and releases platelets and nuetrophils in response to 
bleeding and infections 116-118. However, aside from these functions the spleen is 
the site of extramedullary hematopoiesis. In times of stress and disease when 
bone marrow cannot fulfill the demand for new cells, the spleen acts as a 
secondary hematopoietic center118. This is not surprising since the spleen is a 
site of hematopoiesis during gestation 104. Recent studies have shown cells with 
multi-lineage capability are found within the spleen and the spleen has been 
recognized not just as a secondary center for hematopoiesis but also a storage 
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site for multiple stem cell lineages. Many studies have linked this to a 
developmental origin called the aorta-gonad-mesonephros (AGM) 119. The AGM 
region is the first site for hematopoiesis, which then migrates to the liver and 
spleen, until ultimately the bone marrow takes over as the primary site of 
hematopoiesis 120, 121. Recent studies have shown the AGM has a broader cell 
lineage potential than just producing CD45+ hematopoietic cells. When CD45-
cells were harvested from the AGM region of mice expressing green 
fluorescence protein (GFP) and transplanted into the liver of neonatal mice 122-
124, the transplanted cells were found not only in the bone marrow and spleen but 
also non-hematopoietic tissue as well- liver, kidney, lung, small intestine, 
vascular wall and uterus 125-131. Literature suggests that stem cells with multi-
lineage potential are found in the spleen as a result of early migration pattern 
from the AGM region [ref]. This leads to the idea of how niches could be formed 
not just within the spleen but various locations in the body due to early 
gestational development and stem cell migrations along developmental axis 122, 
132. It is currently believed that tissue-specific progenitor cells reside within niches 
proximal to the cells types they will regenerate. 
Recent studies have led to the identification of several EPC niches in the 
spleen, liver, adipose tissue, adventitial tissue, and small intestine 125-131. Using a 
parabiosis model coupled with a reverse bone marrow transplant and hindlimb 
ischemia, Aicher et aI., 99 set out to discern the actually percentage of EPC that 
come from non-bone marrow niches. In this study 74 ± 13% of Circulating 
progenitor cells are non-bone marrow derived and incorporated into hindlimb 
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ischemia (HLI) of rats. In addition as previously mentioned organs such as the 
liver and small intestine have a considerable number of resident progenitor cells, 
within progenitor cell niches. Sex-mismatched transplant of liver and small 
intestine of rats followed by the induction of HLI, showed that 4.7 ± 3.7% small 
intestine-derived endothelial progenitors incorporated in the ischemic tissue of 
HLI models and contributed to vasculogenesis, while the liver contributed 6.3 ± 
2.2% 133. Within the adipose tissue, there is the stromal vascular fraction (SVF). 
This fraction has angiogenic capacity equivalent to that of bone marrow-derived 
EPCs when injected after HLI 134.,Other studies have shown that the lung and 
skeletal muscle also possess endothelial progenitor cell niches. However, it is 
unclear whether these cells are truly tissue -resident or whether they are derived 
from the bone marrow 131,135. Vascular tissue itself has also -been studied and a 
"vasculogenic zone" was has been recently discovered. This zone lies between 
the adventitial and media of the vessel wa1l126. Cells within this vasculogenic 
zone have been identified as CD34+/Tie2+/KDR+NE-Cadherin+ ,capable of 
differentiating into mature endothelial cells and form capillary like sprouts in 
Mitragel 126. 
Hill et al., 136 performed a series of experiments with male patients who 
had varying degrees of cardiovascular risk but had no history of cardiovascular 
disease. Peripherial blood was taken and EPC numbers were significantly 
reduced in patients with elevated cholesterol levels, hypertension and diabetics. 
They also found a significant inverse correlation between EPC numbers and 
Framingham scores of these patients. EPC depletion could be a by-product of 
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increased oxidative stress or other physiologic process within the patient. 
However, this decrease could also be due to continuos endothelial injury and 
EPC exhaustion compounding the risk for developing cardiovascular diseases. 
Previous studies have also shown that a decrease of circulating stem cells can 
be an important determinant of age-related conditions 136. Injection of EPC into 
the circulation of ischemic asythmic models shows a striking result, animals have 
increased limb salvage and increased angiogenesis of the ischemic leg 137. 
By studying how pollutants affect EPCs we may be able to understand 
their mechanism of cardiovascular toxicity and to assess the cardiovascular 
disease risk due to pollutant exposure. 
Goals of the project 
The overall thesis of the work presented here is that exposure to environmental 
pollutants such as acrolein could deplete EPC levels or interfere with EPC 
mobilization, and thereby increasing the risk of developing cardiovascular 
disease and endothelial dysfunction. Although EPCs express high levels of 
manganese superoxide dismutase (MnSOD) and therefore are likely to be 
resistant to oxidative injury, recent studies have shown that exposure to 
tobacco smoke or the cardiovascular disease decreases EPC levels. 
Nevertheless, the mechanisms by which EPC levels are decreased under these 
conditions remain completely unknown .. Hence, the aim of this project was to 
examine how inhalation exposure to a ubiquitous environmental pollutant such as 
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acrolein affects circulating EPC levels (Aim 1) and to understand the mechanism 
by which acrolein inhalation affects EPC mobilization (Aim 2) . To assess the 
functional significance of the effects of acrolein on EPCs, I also studied how 
exposure to this aldehyde affects EPC mobilization after hind-limb (Aim 3). The 
main purpose of these studies was to learn more about the mechanisms of 
cardiovascular toxicity due to acrolein exposure. 
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CHAPTER II: 
ACROLEIN INHALATION DECREASES CIRCULATING LEVELS OF 
ENDOTHELIAL PROGENITOR CELLS 
Introduction 
Several epidemiological studies show that exposure to combustion products 
increases the risk of developing cardiovascular disease. In many large 
population-based studies, long-term exposure to traffic-generated combustion 
products has been found to be associated with an increased risk for coronary 
heart disease 138, atherosclerosis 139 and fatal myocardial infarction 140. Likewise, 
exposure to products of wood or coal combustion is linked to increases in blood 
pressure and cardiovascular mortality 141,142. Moreover, individuals such as bus 
drivers 143, chimney sweeps 144 and firefighters 145, who are repeatedly exposed to 
combustion products, have significantly higher rates of cardiovascular mortality 
than the general population. In addition, extensive data show that cardiovascular 
disease and mortality are increased by exposure to combustion products 
generated during smoking 146 or present in secondhand tobacco smoke 147. 
Experimental data with humans or animals exposed to automobile exhaust 148 or 
tobacco smoke 146, 147 support these epidemiologic findings. These studies 
suggest that combustion products induce adverse cardiovascular effects. 
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Nonetheless, the chemicals that mediate the cardiovascular toxicity of 
combustion products are unidentified. 
Combustion of organic material results in the generation of a complex 
chemical mixture. The composition of this mixture varies with the source; 
however, one of the chemicals common to all combustion sources is acrolein. It 
is produced in high amounts during combustion of organic material in any form 
(coal, wood, paper, cotton, gasoline, diesel or tobacco)149. Recent estimates 
show that high levels of acrolein (between 6-8 ppm 150) are present in exhaust 
gases from petrol and diesel engine vehicles, and tobacco smoke (100-600 
1l9/cigarette)151 generates up to 50-70 ppm acrolein. Acrolein is a highly reactive 
and toxic chemical,76, 152 which could account, at least in part, for the 
cardiovascular toxicity induced by combustion products. Our previous studies 
showed that acrolein inhalation leads to endothelial dysfunction in susceptible 
mice 153. Endothelial injury is also an early and integral feature of the 
cardiovascular toxicity of automobile eXhaust148, tobacco 146,147 and wood 
smoke 154 exposures. However, mechanisms by which these exposures affect 
endothelial health remain unclear. Recent work suggests that endothelial repair 
and regeneration depends, in part, upon circulating cells with pro-angiogenic 
potential86. These cells with pro-angiogenic potential have been coined 
Endothelial progenitor cells (EPCs) and are also known as Flk+/Sca+ cells, they 
possess both endothelial markers and stem cell markers. The blood level of Flk-
1 + ISca-1 + cells is a sensitive index of endothelial health and is inversely 
correlated with cardiovascular disease risk86. This current study was, therefore, 
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designed to test the hypothesis that acrolein exposure adversely affects the 
number and mobilization of circulating Flk-1 +tSca-1 + cells. 
Methods 
Acrolein Exposure 
Acrolein atmospheres were generated from liquid acrolein (Sigma-Aldrich, St. 
Louis, MO, USA; ~90%; diluted in dH20, 1 :10). Acrolein exposure was 
performed using a custom vapor system (Teague Enterprises, Inc., Woodland, 
CA, USA) with a primary chamber as a constant source, and acrolein vapors 
diluted with HEPA-filtered room air in a secondary chamber. During exposure, 
acrolein concentration was continuously monitored using an in-line photo 
ionization detector (ppb RAE+, Rae Industries, Sunnyvale, CA, USA) upstream of 
the cage insert vapor delivery unit (Teague Enterprises, Inc.) mounted on a 
standard polycarbonate rat cage (41 cm x 34 cm x 21 cm; ==-31 L). Air or acrolein 
was distributed through a fine mesh screen at 3 Ipm by delivery units with a 
cyclone-type top that distribute air within 10% of the mean concentration at six 
locations in the cage (Scheme 3). Exposure cages were placed partially over 
heating pads (==-22 °C) to allow mice to select preferable temperature. Mice were 
exposed to 5ppm acrolein for 2 or 6 h (5010±49ppb of 2 different exposures) or 
to 1 ppm acrolein for 4 days (1 ,053±22ppb of 5 different exposures) 
(Scheme 4). 
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Scheme 3: acrolein inhalation setup 
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Circulating endothelial progenitor cell mobilization 
Acrolein (1 ppm 6hr/4d) and Air (HEPA air 6hr/4d) exposed mice were injected 
with saline of VEGF165 for 4 consecutive days. Immediately after the final 
exposure, VEGF-injected mice received the CXCR4 antagonist, AMD3100, and 
control mice received saline. Mice were the euthanized 1 hr after AMD31 00 or 
saline injection (Scheme 5). 
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Scheme 5: VEGF/AMD3100 treatment regime 
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Peripheral blood mononuclear cells and flow cytometry 
Whole blood (300-400 IJI) was lysed (4 ml; BD PharmLyse, BD BioSciences, San 
Jose, CA, USA; 10 min, RT) and after centrifugation (5 min, 400xg, RT), the 
supernatant was aspirated and the lysing/centrifugation/aspiration steps were 
repeated. The cell pellet was resuspended in 1 % FBS/PBS and divided into 2 
equal fractions. One fraction was fluorescently-Iabeled with anti-Sca-1 and anti-
Flk-1 antibodies tagged with FITC (Fluorescein Isothiocyanate) and APC 
(Allophycocyanin), respectively. Following centrifugation (5 min, 400xg, RT), 
mononuclear cells were re-suspended in 1 % FBS/PBS (20 IJI) with murine 
CD16/CD32 Fc Block to prevent non-specific binding to cell surface markers (0.5 
IJg; BD Biosciences) and incubated for 10 min on ice. The FITC-Sca-1 (1 IJg; BD 
BioSciences) and APC-Flk-1 (1 IJg, BD BioSciences) antibodies or appropriate 
isotype controls(1 IJg; BD BioSciences) were added to cells (23 IJI) and incubated 
for 30 min on ice. Cells were then washed with 1 % FBS/PBS (400 IJI) and 
centrifuged (5 min, 400xg, RT). Cells re-suspended in 1 % FBS/PBS (400 IJI) 
were analyzed using a LSRII flow cytometer (BD BioSciences). Based on 
forward and side scatter, small non-debris events in a sub-lymphocyte population 
(3-5 IJm; sized using fluorescent beads, BD Biosciences) were gated 
electronically and displayed in a two-color dot plot. Data were subsequently 
analyzed using FACSDiva v6.0 software (BD Biosciences), and double positive 
events were normalized per 50,000 events or per IJI of assay volume. 
Preliminary flow cytometry data indicated that ~98% of circulating Flk-1+/Sca-1+ 
cells were also CD45+ (1 IJg, PerCP-CD45; BD Biosciences). 
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Endothelial progenitor cell characterization 
For better characterization EPCs were mobilized. Mice were injected with saline 
or VEGF165 saline (100 I-Ig/kg/d; Peprotech, Inc., Rocky Hill, NJ, USA) (n=4,4) 
daily for 4 consecutive days, on the 5th day received CXCR4 antagonist, 
AMD3100, and control mice received saline (5mg/kg, Lp., 1001-11; Sigma-Aldrich) 
(n=4,4). Mice were euthanized 1 h after AMD31 00 or saline injection. Whole 
blood (1mL) was lysed (9 ml; BD PharmLyse, BD BioSciences, San Jose, CA, 
USA; 10 min, RT) and after centrifugation (5 min, 400xg, RT), the supernatant 
was aspirated and the lysing/centrifugation/aspiration steps were repeated. After 
washing cells were resuspended in 2% FBS/PBS with FcBlock for staining. All 
staining antibodies were purchased from eBioscience (San Diego). The following 
antibodies were used for analysis in three different groupings: Stem cell marker 
panel 1 : Anti-Mouse CD150 FITC, Anti-Mouse Ly-6A1E (Sca-1) PE, Anti-Mouse 
CD115 (c-fms) PerCP-eFluor® 710, Anti-Mouse CD48 PE-Cy7, Anti-Mouse 
CD309 (FLK1) APC, Anti-Mouse CD11 b APC-eFluor® 780, Anti-Mouse CD34 
eFluor® 450, Anti-Mouse CD38 Biotin-Streptavidin 605 nanocrystal; Stem cell 
marker panel 2: Anti-Mouse CD133 (Prominin-1) Biotin 605, Anti-Mouse CD150 
FITC, Anti-Mouse Ly-6A1E (Sca-1) PE, Anti-Mouse CD115 (c-fms) PerCP-
eFluor® 710, Anti-Mouse CD48 PE-Cy7, Anti-Mouse CD309 (FLK1) APC, Anti-
Mouse CD11 b APC-eFluor® 780, Anti-Mouse CD34 eFluor® 450; T and 8-cell 
marker panel 3: Anti-Mouse CD8a PerCP-Cy5.5, Anti-Mouse CD3 APC-eFluor® 
780, Anti-Human/Mouse CD45R (B220) eFluor® 450, Anti-Mouse CD4 eFluor® 
605NC, Anti-Mouse CD31 (PECAM-1) FITC, Anti-Mouse Ly-6A1E (Sca-1) PE, 
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Anti-Mouse C0309 (FLK1) APC, and Anti-Mouse C019 PE-Cy7. Cells were 
analyzed by flow cytometry (BO LSRII, BioSciences) and data were analyzed 
using FlowJo (TreeStar Software; Ashland Oregon). 
Isolation and culture of bone marrow-derived cells (BMDCs) 
Bone marrow was aspirated from femur and tibia of both legs with 1 mL HBSS 
(Clonetics/Lonza, Walkersville, MO, USA), and mononuclear cells were 
separated by Ficoll gradient centrifugation (Ficoll-Paque PREMIUM, GE 
Healthcare, Piscataway, NJ, USA; 400xg, 20 min, 4°C). Trypan blue-viable cells 
(2-4x1 06 cells per mouse) were isolated and 8x105 cells were seeded on 
fibronectin-coated, 8-well chamber slides (10% human fibronectin, Sigma-
Aldrich) in 500 IJL endothelial basal media (Clonetics/Lonza) supplemented with 
20% FBS (Invitrogen, Carlsbad, CA, USA), human endothelial growth factor 
(hEGF), hydrocortisone, gentamycin/amphotericin B (GA) and bovine brain 
extract (BBE)(SingleQuot®, Clonetics/Lonza) under standard cell culture 
conditions (3rC, 5% CO2)155. On day 7, cells were incubated with Oil-acLOL 
(2.4 IJg/mL, Invitrogen) in media for 3 h. After media was removed, cells were 
washed three times with PBS, fixed in 4 % PFAlPBS (pH 7.4; RT) for 10 min, and 
then incubated with FITC-UE-Iectin (50 IJgI mL, Sigma-Aldrich) at 3rC for 30 
min. For labeling of Flk-1 and Sca-1, cells were incubated with FITC-Sca-1 (1 :25; 
BO BioSciences) and APC-Flk-1 (1 :15, BO BioSciences) antibodies for 1 h at RT. 
Cells were washed three times with PBS before slides were stained with OAPI-
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containing Slow Fade® Gold anti-fade reagent (Invitrogen). DiI-acLDL and FITC-
UE-Iectin double-positive cells were counted in 10 random fields. 
Blood counts and plasma biochemistry 
After select exposures, 100 1-11 of blood were used for complete blood count 
analysis (CBC; Hemavet 500, Coulter Counter, Oxford, CT). Plasma total, HDL 
and LDL cholesterol, triglycerides, total protein, albumin (Cholesterol CII 
Enzymatic Kit; L-Type TG-H Kit; Bradford reagent, bromocresol green, Wako, 
Richmond, VA, USA), AL T, AST (Infinity, ThermoElectron, Louisville, CO, USA), 
CK and LDH (Promega, Madison, WI, USA) levels were measured using 
commercially available assay reagents as indicated. Assays were performed 
using calibrated standards in 96-well plates or using a Cobas Mira Plus 5600 
Autoanalyzer (Roche, Indianapolis, IN, USA). Plasma NOx level (stable NO 
metabolites, nitrate and nitrite; 25 1-11) was measured fluorimetrically according to 
manufacturer's instructions (NOx kit; Calbiochem, Darmstadt, Germany). 
Isolated aorta studies 
Thoracic aorta were isolated and tested for intact VEGF signaling. Isolated aortas 




Thoracic aortas were isolated and vascular reactivity was assayed as described 
previously 11. Briefly, one 3-4-mm ring per mouse was hung on stainless steel 
hooks in 15-ml water-jacketed organ baths in physiological salt solution (PSS) 
bubbled with 95% O2 and 5% CO2 at 3rC. The composition of PSS was (in 
mM): NaCI, 130; KCI, 4.7; MgS04·7H20, 1.17; KH2P04, 1.18; NaHC03, 14.9; 
CaCI2, 2.0; glucose, 5.0; pH 7.4. Rings (::=1 g loading tension) were contracted 
with 100 mM potassium solution (2 times) followed by cumulative concentrations 
of phenylephrine (PE; 0.1 nM - 10 IJM). PE-precontracted rings were relaxed 
with cumulative concentrations of acetylcholine (ACh; 0.1 nM - 10 IJM) or of 
sodium nitroprusside (SNP; 0.1 nM -10 IJM) to measure endothelium-dependent 
or -independent relaxation, respectively. Vessel contraction was quantified as 
mg tension, active stress (in mN/mm2) or normalized as percentage of the 
maximum PE contraction. Relaxation was calculated as percentage reduction of 
PE-induced tension. The effective concentration producing 50% response (EC50) 
was assessed by normalizing cumulative concentration responses to 100%, 
plotting the response vs. the log [molar] agonist, and then interpolating the EC50 
value. 
Western blot analyses 
Bone marrow aspirates were centrifuged and pellets were suspended in lysis 
buffer (25 mM HEPES, pH 7.0; 1 mM EOTA; 1 mM EGT A; 1 % Nonidet P40; 1 % 
SOS) supplemented with 1:100 protease inhibitor cocktail (Sigma-Aldrich), 1:100 
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phosphatase inhibitor cocktail and 50mM N-ethylmaleimide (NEM; Pierce, 
Rockford, IL, USA). After sonication, samples were centrifuged (4,OOOxg, 15 
min, 4°C) and supernatants were used for detection of protein-acrolein adducts 
by Western blotting. Pulverized aortas were lysed in RIPA buffer (50mM 
Tris-HCI, pH 7.4, 150mM NaCl, 1mM EOTA, 0.25% sodium desoxycholate, 1 % 
NP-40; 1: 1 00 protease inhibitor cocktail; 1: 1 00 phosphatase inhibitor), sonicated 
and centrifuged (13,OOOxg, 15 min, 4°C). Heart was homogenized in membrane 
preparation lysis buffer (25mM Tris; 0.5mM EOTA; 0.5mM EGTA; protease 
inhibitor 1 :100 dilution; phosphatase inhibitor, 1 :100; pH 7.5) and centrifuged 
(14,OOOxg, 15 min, 4°C). Pellet was resuspended in lysis buffer supplemented 
with 1 % NP-40 and incubated for 4h 156. After incubation and second 
centrifugation, the supernatant was collected as membrane fraction. Lungs were 
homogenized in ice cold lysis buffer (50mM Tris-HCL; 1mM EOTA; 1mM EGTA; 
protease inhibitor, 1:100; phosphatase inhibitor, 1:100 dilution; pH 7.4). Lysates 
were centrifuged (14,OOOxg, 15 min, 4°C) and supernatants used for Western 
blotting 157. 
Total protein was measured using a commercially available kit (Bradford, Bio-
Rad, Hercules, CA, USA). For Western blot analysis of protein-acrolein adducts, 
protein samples (150 I-Ig) in 5x sample buffer (312.5 mM Tris base, pH 6.8 [Bio-
Rad] or, 10% Glycerol, 11.5% SOS, 0.1 % Bromphenol) supplemented with 50 
mM NEM were separated under non-reducing conditions, whereas all other 
proteins (30-100 I-Ig) were separated under reducing conditions (buffer 
supplemented with 50 mM OTT). Briefly, heat-denatured (5 min, 95°C) protein 
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samples were separated by SDS-PAGE and transferred to PVDF membranes 
(Bio-Rad). Membranes were processed by standard immunodetection 
techniques using a rabbit polyclonal antibody against KlH (Keyhole Limpet 
hemocyanin)-protein-acrolein adduct 158 or using a commercially available 
antibody against Phospho-Akt (Ser473), Akt, Phospho-eNOS (Ser1177), eNOS 
(BD Biosciences, 1: 1000), Phospho-p42/44 (Thr202ITyr204), p42/44 (1: 1 000; 
Cell Signaling) or VEGFR-2 (1 :2S0; Santa Cruz) or MMP-9 (1 :SOOO, Chemicon, 
Millipore, Temecula, CA, USA). Western blots were developed using ECl ® plus 
reagent (Amersham Biosciences, Piscataway, NJ, USA) and detected with a 
Typhoon 9400 variable mode imager (Amersham Biosciences). Actin antibody 
(1 :2000, Sigma-Aldrich) detection or amido-black staining was used as loading 
control. Quantification of band intensities was performed using Image Quant Tl 
software (Amersham Biosciences). 
Histology and immunohistochemistry 
Pelvic bones were formalin-fixed (10 % neutral buffered formalin) for 24h, 
decalcified in Immunocal® (Decal Chemical Corp., Tallman, NY) for 6h, and 
washed in running tap water (O.Sh). Paraffin-embedded sections (S IJm) of pelvic 
bones were stained with hematoxylin/eosin, anti-protein-acrolein adduct (rabbit 
polyclonal; 1:1 ,OOO), or normal rabbit or goat IgG (as negative controls) 158. A 
goat anti-rabbit secondary antibody and a Vector Elite staining kit with 
diaminobenzadine (Dako) as chromagen were used. 
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MoFlow cell sorting and 101 staining 
Whole blood (1000 1-11) was lysed (10 ml; BD PharmLyse, BD BioSciences, San 
Jose, CA, USA; 10 min, RT) and after centrifugation (5 min, 400xg, RT), the 
supernatant was aspirated and the lysing/centrifugation/aspiration steps were 
repeated. The cell pellet was resuspended in 1 % FBS/PBS and divided into 2 
equal fractions (i.e., isotype control or Flk-1/Sca-1 labeling). After centrifugation 
(5 min, 400xg, RT), mononuclear cells were re-suspended in 1 % FBS/PBS with 
murine CD16/CD32 Fc Block (0.5 I-Ig; BD Biosciences), incubated for 10 min on 
ice, followed by 30 min incubation on ice with anti-Sca-1 (FITC, 1 I-Ig; BD 
BioSciences) and anti-Flk-1 (1 I-Ig, BD BioSciences) antibodies or appropriate 
isotype control (1 I-Ig; BD BioSciences). Cells were then washed with 1 % 
FBS/PBS and centrifuged (5 min, 400xg, RT). Based on forward and side scatter, 
small non-debris events were gated electronically and 200 labeled Flk-1 +/Sca-1 + 
cells were sorted into a 1.7 uL centrifuge tube containing 2 % FBS/PBS using 
MoFlo® (Beckman-Coulter). Cells were fixed with 1 % paraformaldehyde for 5 
min. on ice. Triton-100X was then added to increase the permeability for 5 min. 
on ice. Cells were then washed using 0.1 % Triton-1 OOX wash buffer, spun down 
at 3rpm for 5 min. then aspirated. Cells were then stained with murine anti-ID1 
(1 :50; Santa Cruze) for 30 min. in 0.1 % Triton on ice, then washed with 0.1 % 
Triton wash buffer and aspirated. Cells were stained using secondary anti-rabbit 
PE fluorophore (1 :25;). Cells were once again washed with 2 % PBS/FBS spun 
down and aspirated. Then 100uL of 2 % FBS/PBS was added and then cell spun 
onto a cytospin slide at 300Xg. Slides mounted in DAPI-containing Slow Fade® 
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Gold anti-fade reagent (Invitrogen), and viewed using a Zeiss confocal 
microscope. 
Results 
Flk+/Sca+ Cell characterization 
To better understand the selective nature of acrolein inhibition, a more extensive 
screen of antigenic markers on Flk-1+/Sca-1+ cells (stem/progenitor and B-/T-cell 
markers) from saline and VEGF/AMD3100-treated mice was conducted by flow 
cytometry. VEGF/AMD3100 significantly increased Flk-1 +JSca-1 + cells 
expressing a variety of stem and B-/T -cell antigenic markers especially cells co-
expressing CD31/CD45R(B220)JCD133 and CD31/CD45R(B220)/CD19 (Fig. 
2A-F). 
Effects of acrolein on circulating Flk-1+/ Sca-1+ cells 
Analysis of the mononuclear cell population of peripheral blood showed that Flk-
1 +/Sca-1 + cells were a relatively small (3-5 j.Jm), sub-lymphocytic, non-debris cell 
population with further characterization showing stem and endothelial cell 
markers (Figs. 3A-2E). 
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Figure 2 
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Figure 2: Hierarchical relationships of Flk+/Sca+ Cells.: A-B, Progenitor cell 
antigens, and, C-D, lymphocytic differentiation marker antigens expressed on 
Flk-1/Sca-1 cells. ,E, Progenitor cell antigens, and, F, lymphocytic differentiation 
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Figure 3: Characterization of Flk-1+/Sca-1 + progenitor cells by flow 
cytometry and microscopy. Representative dot plots of A, forward-
(FSC) and side-scatter (SSC) of circulating cells and size beads indicating 
an approximate size range of Flk-1+/Sca-1+ cells (3-5IJm) Dot plots of 
SSC and PerCP-CD45 fluorescence of Flk-1 + /Sca-1 + cells representing 
CD45 positive (CD45+, 98.5±O.3 %) and CD45 negative cells (CD45-, 
1.2±O.3 %). Dot plots of FSC and PE-CXCR4 fluorescence of Flk-1 + /Sca-
1 + cells that are CXCR4 positive (97.2%). B, Brightfield and confocal 
images of Flk-1/Sca-1-double positive cells sorted by MoFlo for 
immunofluorescence detection of antigen co-localization. C, Confocal 
image of sorted Flk-1+/Sca-1+ cells stained with Id1 antibody. Nuclei were 
stained with DAPI. 
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Acrolein exposure induced a selective and dose-dependent decrease of 
circulating Flk-1+/Sca-1+ cells (Fig. 4C). The number of Flk-1+/Sca-1+ cells was 
significantly reduced by 77±10 % following exposure to 1 ppm acrolein for 4 
consecutive days (6h/d; air: 413±109 cells per SO,OOO events; acrolein: 97±19 
cells per SO,OOO events; n=8, 8; p<O.OS). However, acrolein exposures (1ppm; 
6h/d) for 1,2, or 4 days did not affect the number of circulating Sca-1+ cells (Fig. 
40). Exposure of mice to a higher dose of acrolein (S ppm; 6h), though, 
decreased Flk-1+/Sca-1+ cells significantly by 43±10 % compared to air-exposed 
mice (air: 4.3±0.7 cells/ IJL; acrolein: 2.4±0.4 cells/ IJL, n=8, 8; p<O.OS; Fig. 4E). 
A brief acrolein exposure (Sppm; 2h), however, did not alter circulating Flk-
1 +/Sca-1 + cells (air: 6.3±2.4 cells/ IJL; acrolein: 7. 7±1.4 cells/ IJL, n=4, 4; p<O.OS) 
or Sca-1+ cell level. Acrolein exposure of O.S ppm (6h/d x 4d) had no effect on 
the number of circulating Flk-1 + /Sca-1 + or Sca-1 + cells as compared with air 
controls indicating a narrow threshold range of acrolein action. Furthermore, 
mice allowed 7 days of recovery after a 4-day acrolein (1 ppm, 6h/d) exposure 
had similar numbers of circulating Flk-1+/Sca-1+ cells compared with air-exposed 
controls (Fig. 4E). Although 1 ppm acrolein (6h/d x 4d) did not alter plasma lipids 
(Table 7) or leukocyte blood cell counts, a 6h exposure to a higher acrolein level 
(S ppm) significantly decreased leukocyte blood cell counts (Table 8). Acrolein 
exposure increased Annexin V/7AAD staining in circulating Flk-1/Sca-1 double 
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Figure 3: Effects of acrolein on circulating progenitor cells. A, Flow 
cytometry analysis of forward- (FSC) and side-scatter (SSC) of peripheral 
blood mononuclear cells of mice breathing filtered air or acrolein (1ppm, 
6h/day, 4 days). B, Representative two color (APC-Flk-1 and FITC-Sca-1) 
flow cytometry dot plots of circulating Flk-1 + /Sca-1 + cells in peripheral 
blood of mice after 4 days of exposure to filtered air or acrolein. Levels of 
C, Flk-1+/Sca-1+ cells and 0, Sca-1+ cells in peripheral blood after 
breathing filtered air or acrolein for indicated days (n=8-12). E, Flk-1+/Sca-
1 + cells in blood obtained from mice breathing filtered air or 5 ppm acrolein 
for 2 or 6h. F, Flk-1+/Sca-1+ cells in blood of mice breathing air or 1 ppm 
acrolein (6h/d, 4d) and after 7 days recovery G, Representative dot plots 
of APC-Flk-1 and FITC-Sca-1 double positive cells stained for 7-AAD 
(necrosis marker) and Annexin V (apoptosis marker), and quantification of 
percentage Annexin V and 7 -AAD stained cells from air and acrolein-
exposed mice. (n=4; * p<O.05). 
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Table 7 
Blood and plasma variables in mice exposed to air or acrolein. 
Air Acrolein, 1 ppm Air Acrolein.5ppm 
Cholesterota 73.2:t3.1 70.1%2.7 60.9%4.1 52.2:1::0.3 
HOL' 54.6:t3.2 45.6:*:3.6 45.8:*:3.2 50.2:1::0.3 
LOLa 10.3:1::0.2 10.9:1::0.7 8.1 :1::0.6 9.4:1::0.2 
T riglyceridesl 17.9:*:3.1 14.5:*:1.9 24.8%4.7 17.7:1::0.3 
TPb 4.1:1::0.1 3.8:1::0.1 3.7:1::0.1 3.7:1::0.8 
ALBb 2.7:1::0.1 2.7:1::0.1 2.5:1::0.1 2.5:1::0.9 
LOHC 167.6:*:17.2 127.2:*:9.9 264.5%26.1 167.5:*:12.1· 
CKe 261.6%21.2 245.1:*:30.1 198:t8.2 247:t5.3 
ALT' 56.5:*:7.8 48.2:i:6.4 25.7:*:3.6 25.8:1::0.9 
ASTc 42.2*7.3 ~5.9*3.9 62.8:t8.7 69.3:*:10.7 
Male, 12-14 week old mice were exposed to air or 1 ppm acrolein (6h1d, 4d. n=11 
mice/group) or 5 ppm acrolein (6h1d. 1d. n=4 mice/group). Values are mean:*: SEM. 
Abbr: HOL. high density lipoprotein cholesterol: LOL, low density lipoprotein cholesterol; 
TP, total protein; ALB. albumin; LOH. lactate dehydrogenase; CK, creatine kinase: AL T, 
alanine aminotransferase; AST, aspartate aminotransferase. Units: I = [mg/dL]. b = 
[g/dL). C = [UIL]; ., p<O.05 VI. Air-matched group. 
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Table 8 
Complete blood count in mice exposed to air or acrolein. 
Air Acrolein.1ppm Air Acrolein, 5 ppm 
waC· 2370:t585 1775~93 2690~81 93~3· 
NE~ 362%64 355:t51 472%61 138*16· 
LYI 1942:t518 1448~62 213~25 752~1· 
Mea 57*15 60*10 78*15 35:t5* 
RBCb 9.03~.30 8,92~.24 8.18~.27 8.24~.26 
HCt (%) 42.2*1.2 41.4*1.3 37.4*1.1 36.9*1.2 
Hbc 11.1~.3 11.1~.3 11.3~.1 12.2~.2 
MCVd 46.9~.3 46.3~.6 45.7~.3 44.8~.4 
MCH' 12.2~.1 12.4~.2 14.3~.1 14.4~.2 
MCHCc 26.1~.1 26.8~.5 31.2~.3 32.1~.3 
ROW(%) 17.3~.5 17.5*1.7 17.3~.3 16.7~.1 
PLTI 835:t50 789~6 845~7 758~8 
MPVd 3.8~.1 3.8~.1 4.1~.1 3.9~.2 
Male, 12-14 week old mice were exposed to air or 1 ppm acrolein (6h1d. 4d. n=8 
mice/group) or 5 ppm acrolein (6hld. 1d, n=4 mice/group). Values are mean * SEM. 
Abbr. WBC. white blood cells; NE. neulrophils: LY.lymphocytes: MO, monocytes; RBC. 
red blood cells; HCt. hematocrit; Hb. hemoglobin; MCV, mean corpuscular volume; 
MCH. mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin 
concentration; ROW, red cell distribution width; PLT. platelets; MPV. mean platelet 
volume. Units: a = [x101/fJL). b = [x106/fJL), C = (g/dL). d = [fL). • = [pg]; *, p<0.05 VI. air-
matched group. 
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Acrolein exposure increased number of bone marrow-derived cells (8MOC) 
To further evaluate the condition of the EPC within the bone marrow culture was 
performed. Acrolein exposure increased the number of Dil-acLDLlFITC-UE-
lectin-double positive cells in culture on day 7 (Fig. 5). After 7 days of culture, 
outgrowths from bone marrow-derived DiI-acLDLlFITC-UE-lectin-double positive 
cells (Fig. 58), had more cells from acrolein-exposed mice than air-exposed as 
indicated by DAPI staining (nuclear; blue fluorescence; Fig. 58). Furthermore, 
the cells positive for Dil-acLDL (red fluorescence) and FITC-UE-Iectin (green 
fluorescence) were increased by acrolein exposure compared with air-exposed 
controls (Fig. 58). Image overlay showed co-localization of EPCs markers (Dil-
acLDL, FITC-UE-Iectin) indicating that acrolein enhanced the proliferative 
capacity of endothelial progenitor-like cells (orange) in culture. Compared with 
cells from air-exposed (control) mice, there was a 3- to 3.6-fold increase in the 
Dil-acLDLlITC-UE-lectin double positive cells isolated from mice exposed to 
acrolein (5 ppm, 6h; Fig. 5C; 1 ppm, 4d; Fig. 50) after 7 days in culture. The 
identification of these proliferating cells as endothelial progenitor-like cells was 
also supported by immunocytochemical staining of cultured BMDC for APC-Flk-1 
and FITC-Sca-1 (i.e., markers used in flow cytometry) on culture day 7. Thus, in 
comparison with air, acrolein exposure (1 ppm, 4d) increased Flk-1+t Sca-1+ cells 
by 1.7 -fold. Taken together, these data showed that acrolein exposure enhanced 
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Figure 5: Acrolein increases proliferation of bone marrow-derived cells. 
Representative fluorescence images (upper panels) and the number of 
(lower panels) of Dil-acLDL+/FITC-UE-lectin+ cells isolated from bone 
marrow of mice exposed to air or B, 5 ppm acrolein for 6h C, or 1 ppm 
acrolein (6h/d, 4 days). Mononuclear cells were isolated from the bone 
marrow and grown in culture for 7 days. Cells were labeled with DiI-acLDL 
and FITC-UE-Iectin and nuclei were stained with DAPI. Merged images 
show co-localization of both markers in orange (i.e., double-positive cells). 
D, Representative fluorescence images (upper panel) and analysis (lower 
panel) of Flk-1+/Sca-1+-cells from mice exposed to air or 1 ppm acrolein 
(6h/d, 4d) after day 7 of culture. Cells were labeled with FITC-Flk-1 and 
APC-Sca-1 and with DAPI for nuclear staining. Merged images show co-
localization of the markers. Changes in the number of Dil-acLDL +/FITC-
UE-Iectin+ and Flk-1 +/Sca-1 + cells are presented as fold increase in double 
positive cells compared with controls (n=4; * p<O.05, air vs. acrolein 
exposure). 
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Protein acrolein adducts 
To determine whether acrolein could directly reach the bone marrow cells, we 
examined the abundance of protein-acrolein adducts in plasma and bone marrow 
by Western blotting and immunohistochemistry (Fig. 6). Protein-acrolein adducts 
were detected by Western blotting of plasma (Fig. 6A) and bone marrow Iysates 
(Fig. 78) of air- and acrolein-exposed (1 ppm, 4d) mice. Abundant acrolein 
adducts were observed in proteins with molecular weights of ==250 and ==150 kOa 
in plasma and of ==250, ==37, ==18 and ==17 kOa in the bone marrow. Acrolein 
inhalation led to a significant increase in the intensity of several bands, including 
a 2.5-fold increase in a plasma protein band of ==150 kOa and a 2-fold increase 
for a bone marrow protein band of ==250 kOa, compared with controls (Fig. 6). 
Similarly, immunohistochemical staining of femur (proximal head) cross-sections 
with protein-acrolein adduct antibody was substantially stronger in acrolein-
treated (1 ppm, 4d) bone compared with controls (Fig. 6C). Adduct distribution 
was quite heterogeneous in both acrolein- and air-exposed mice, however, 
distinct, intense positive staining of protein-acrolein adducts was observed in 
blood vessels within the connective tissue as well as in the ostea of the bone 
trabeculae (Fig. 6C, see black arrows). More diffuse staining was present in the 
bone marrow matrix, i.e., hematopoietic tissue (Fig. 6C, yellow arrows), where 
some focal, intense staining was localized to the largest bone marrow cells within 
the endosteum at the border between the bone marrow cavity and compact bone 
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Figure 6: Formation of protein-acrolein adducts. Western blot analyses of 
protein-acrolein adducts in A, plasma or B, bone marrow extracts obtained from 
mice breathing air or 1 ppm acrolein for 4 days (6h/d). Amido-black stain 
(plasma) and actin detection (bone marrow) were used as loading controls. C, 
Bone marrow immunohistochemistry of acrolein antibody staining, air v. acrolein 
inhalation. Data are presented as fold increase of protein-acrolein adducts after 
acrolein exposure compared with air-exposed mice (* p<O.05; n=4-5). 
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Endothelial dysfunction and NO signaling 
The number of circulating Flk-1 + /Sca-1 + cells is in continuous flux due to the 
competing processes of mobilization (e.g., bone marrow/spleen) and recruitment 
to sites of injury (e.g., endothelium). To determine if the acrolein-induced 
decrease in circulating Flk-1+/Sca-1+ cells was due to increased recruitment to 
vascular sites of injury, endothelium function was measured in isolated aorta 
following exposures. No evidence of frank vascular smooth muscle or 
endothelial cell dysfunction was found after 1 ppm acrolein exposure (6h/d x 4d; 
Table 9), which is consistent with a previously published study using 1 ppm 
acrolein exposure in C57BLl6 mice 153. In contrast, brief exposure of mice to 5 
ppm acrolein (6h) induced a modest, yet significant, rightward shift in the 
acetylcholine-mediated vasorelaxation in phenylephrine-precontracted aorta 
indicating endothelial dysfunction (Fig. 7A; Table 9). There was no change in 
total percentage of NO-donor-mediated (sodium nitroprusside, SNP) relaxation, 
although there was a significant leftward shift in aortic sensitivity to SNP (EC50: 




Vascular effects of air or acrolein exposure in mice. 
Air Acrolein, 1 ppm Air Acrolein,S eem 
PhenxleRhrin! (pel 
Tension(mg) 738~74 659z62 1037~156 723:t83 
Active Stress (mN/mm2) 8.9~.9 8.1~1.2 na na 
EC50{nM) 149~15 149~15 151~33 160~6 
p02 6.84~.05 6.84~.05 6.88~.09 6.83~.07 
Ace~lcholine (ACh) 
Relaxation (% PE) -63~ -64~7 -66:t8 -66~ 
EC50(nM) 136~1 195:t82 113~0 180~4· 
p02 6.92~.09 6.92~.15 7.00~.10 6.77~.06t 
Sogium NitroRrusside ,§NP) 
Relaxation (% PE) -121~ ·121z6 -103~ ·104~ 
EC50(nM) 15~3 18~3 16~3 9~1· 
RQ2 7.~1~.1Q 7.§Q~.Q7 7.§4~.09 §.08~.Q§· 
Male. 12-14 week old C57BU6mice were exposed to air or acrolein (1 ppm, 6h1d. 4d or 
5ppm, 6h/d, 1 d). Values are mean ~ SEM. Abbr: HI K+, 100 mM potassium buffer; na, 
not available; EC50 == effective concentration producing 50% response; p02, Q(EC50);; 
• P!O .05 VS. matched air control (n=7..a mice/group); 1 0.1 0>p>0.05 VI. matched"'r 
control. 
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To examine whether acrolein-induced endothelial dysfunction was due to 
changes in nitric oxide (NO) bioavailability, we examined changes in plasma of 
the stable end products (nitrate and nitrite) of the I-arginine/nitric oxide 
biosynthetic pathway otherwise known as NOx, total eNOS, and the 
phosphorylation status of eNOS and Akt, which are critical mediators of 
endothelial signaling and function (Fig. 8). Acrolein exposure at 1 ppm (6h/d x 
4d) or 5ppm (6h) significantly decreased plasma NOx levels by 15 % (air: 100±8 
%; acrolein: 85±4 %; n=8, 8; p<O.05) or 22 % (air: 100±8 %, acrolein; 78±4 %, 
n=8, 8; p<O.05), respectively (Fig. 7C). The acrolein-induced suppression of 
plasma NOx level after 4-day acrolein exposure was reversed by 7 days of 
recovery in acrolein-free air (Fig. 7 A). Similarly, the recovery of plasma NOx 
level coincided with a return of circulating Flk-1+/Sca-1+ cell numbers in acrolein-
exposed mice to the air control level (Fig. 4F). 
Because acrolein exposure decreased both plasma NOx and Flk-1+/Sca-1+ 
cell levels, eNOS protein content was measured in Iysates of lung, heart and 
aorta (Fig. 7C) by Western blotting. Additionally, VEGFR-2 abundance was 
measured by Western blotting in bone marrow Iysates. As shown in Figure 7C, 
acrolein exposure (1 ppm; 6h/d x 4d) did not alter eNOS protein abundance in 
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Figure 7: Endothelial response to acrolein exposure. A, Endothelial function 
assay from aorta of mice exposed to Sppm 6hr acrolein (n=4, * p<O.OS) B, 
NOx levels in plasma of mice breathing filtered air or acrolein (n=8, * 
p<O.OS). C, Western blot analyses of eNOS or VEGFR2 in Iysates of lung, 
heart, aorta or bone marrow of mice breathing filtered air or 1 ppm 
acrolein (6h/d, 4d). Group densitometry data are presented as mean ± 
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Figure 8: Effects of acrolein on enzymatically important constituents of 
EPC mobilization. A, Representative Western blots of phospho-eNOS 
(Ser1177). phospho-Akt (Ser473). eNOS and Akt in Iysates of aortas obtained 
from animals exposed to air or Acrolein (5 ppm/6h) B. Akt and C. MMP-9 in 
Iysates of bone marrow obtained from animals exposed to air or acrolein (5 
ppm/6h). Group data are presented as mean ± SEM. n=4. 
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VEGF+AMD3100-induced mobilization of Flk-1+/Sca-1+ cells 
Because acrolein exposure decreased circulating Flk-1 +/Sca-1 + cells in the 
absence of frank aortic endothelial dysfunction, we tested if acrolein perturbed 
progenitor cell mobilization. Acrolein alone (1 ppm, 4d) significantly decreased 
Flk-1 + / Sca-1 + cells compared with air controls (air + saline: 1.5±0.3 cells/ IJL; 
acrolein + saline: 0.7±0.1 cells/ IJL; n=4, 4; p<0.05; Fig. 9A). As shown before, 
VEGF+AMD3100 treatment led to a 3-fold increase in circulating Flk-1+/Sca-1+ 
cells 159. Acrolein inhalation significantly and specifically impeded 
VEGF+AMD3100-induced Flk-1+/Sca-1+ mobilization (normalized to air control: 
air+VEGF+AMD31 00: 3.0±0.4 cells/ IJL; acrolein+VEGF+AMD31 00: 0.4±0.1 
cells/ IJL, n=8, 8; p<0.05; Fig. 9A). Although VEGF+AMD3100 treatment 
significantly increased Sca-1 + cells (normalized to air control: 
air+VEGF+AMD31 00: 2.8±0.4 cells/ IJL; acrolein+VEGF+AMD31 00: 2.9±0.4 
cells/ IJL, n=8, 8) and overall white blood cell counts, indicating general 
mobilization of both stem cells and leukocytes, these effects were unaltered by 
acrolein exposure (Table 10), indicating that acrolein specifically decreased the 
endothelial progenitor cell population. 
Co-treatment with VEGF+AMD31 00 is known to modify mobilization without 
changing bone marrow cell function 159. Treatment with VEGF+AMD31 00 did not 
alter aortic eNOS or Akt protein levels as analyzed by Western blotting 
regardless of exposure (Fig. 98-C). 
Our results indicate that acrolein at 1 ppm inhibits mobilization of Flk-1 +/Sca-
1 + cells via diminished NO bioavailability and impaired VEGF/ CXCR4 signaling. 
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Henceforth, we studied VEGF signaling in aortas isolated from air- or acrolein- (1 
ppm, 6h/d x 4d) exposed mice. Aortas were incubated ex vivo with VEGF (20 ng/ 
mL) for 15 min and phosphorylation status of Akt (Fig. 90), eNOS (Fig. 9E) and 
ERK (Fig. 9F) proteins was analyzed. In control aortas, VEGF stimulated 
phosphorylation of Akt (2-fold) and eNOS (2-fold) - an effect absent in aortas of 
acrolein-exposed mice (Figs. 90 and 9E). Although VEGF-induced 
phosphorylation of ERK was not influenced by inhalation exposure, acrolein-
exposed aortas had a significantly greater level of basal phospho-ERK (p42/44) 
(Fig. 9F). These findings indicated that acrolein exposure significantly impaired 
VEGF/ CXCR4 signaling - an effect that could account for the diminished levels 
of basal and VEGF+AMD3100-mobilized Flk-1+/ Sca-1+ progenitor cells, as well 
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Figure 9: Effect of acrolein on the mobilization of Flk-1+/Sca-1 + cells. A, 
Representative two color (Flk-1 and Sca-1) flow cytometry dot plots (upper 
panel) of circulating cells in the peripheral blood of mice breathing filtered 
air or 1 ppm acrolein (6h/d, 4 d) after combination of VEGF/AMD3100 
treatment. Levels of Flk-1 + ISca-1 + cells per IJI blood (left y-axis) and Sca-
1 + cells (right y-axis; fold-change relative to air control) of mice breathing 
filtered air or 1 ppm acrolein (6h/d, 4d) after treatment with 
VEGF/AMD3100 (* p<O.05, n=8). B, Representative Western blots and 
densitometric analysis of Akt in bone marrow Iysates obtained from mice 
after saline or VEGF/AMD3100 treatment (n=4). C, Representative 
Western blots and densitometric analysis of eNOS in Iysates of aortas 
obtained from mice breathing air or acrolein (1 ppm, 6h/d, 4d) after saline 
or VEGF+AMD3100 treatment (n=4). O-F, Analysis ofVEGF signaling in 
aortas isolated from mice breathing air or acrolein (1 ppm, 6h/d, 4d) and 
treated with VEGF in autologous plasma for 15 min. Representative 
Western blots and analysis of membranes probed for 0, phospho-Akt 
(Ser473)/total Akt; E, phospho-eNOS (Ser1177)/total eNOS; and F, 
phospho-ERK (Thr202/Tyr204) Itotal ERK (n=3-7; * p<O.05). 
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Table 10 
Compiete blood counts In mice exposed to air or acrolein 
+81111 .... +VEGF+AMD3100 
Au Acrolein, 1 ppm AJr Acrolein, 1 ppm 
wac' 1365+..210 2131:!:368' 763Ot:81 0' 8030±475t 
NEt 422±79 497:t179' 2345!362' 2821!280f 
LY· 897±165 1600!192' 5042±494' 4981:1:2851 
MO' 35±11 61±32' 232:!:1T 22O!161 
RBO 6 72:tO 80 868:tO.33 7.94:tO 46 8 32:tO 47 
HCt (%) 32 2:1:2 3 39 2.t1 5 34.~19 371:1:2 2 
Hb' 9 1:t1 2 119:t06 108:tO 7 111:t05 
MCV" 447:t07 451:tO 2 44 5:tO 3 442:t04 
MCHe 13 3:t0 3 136:tO 1 134:tO 2 135:t03 
MCHO 29.~05 305:tO 3 3O.8:tO 9 302:tO.5 
RDW(%) 165:tO 3 17 3:tO 2 178:tO.2 17 3:tO 3 
PlP 799!122 858:t76 917±'91 809±78 
MPV" 4 4:tO 1 42:t0 1 44:tO 1 42:tO.1 
Made, 12-14 week old mice were exposed to air or 1 ppm acrolein (6hld. 4<1, n=8 
miCe/group) Values are mean t SEM Abbr wac, white blood cells. NE. neutrophlls, 
L Y, lymphocytes, MO. monocytes. RBC. red blood cells, HCt. hematocnt. Hb, 
hemoglobtn, MCV, mean corpuscular volume, MCH, mean corpuscular hemoglobtn, 
MCHC, mean corpuscular hemoglobtn concentration. ROW. red cell distnbubon WIdth, 
PlT,platelets. MPV, mean platelet volume Urnts I:; [x1()3/J.1L), 0: (x1()6/J.1l1, c: (g/dl], d 




Results of the current study showed that inhalation of acrolein suppressed the 
level of Flk-1+/Sca-1+ cells in the peripheral blood and prevented their 
mobilization by VEGF/SDF-1. The effects of acrolein were specific because 
acrolein decreased Flk-1 + /Sca-1 + cells without affecting the level of Sca-1 + cells, 
indicating a unique sensitivity of this heterogeneous cell population to acrolein. 
Effects of acrolein inhalation were, however, transient, and recovery in an 
acrolein-free environment for 7 days led to complete restoration of the level of 
these cells in the peripheral blood. Moreover, the decrease in Flk-1+/Sca-1+ cells 
was associated with decreased plasma NOx level, prevention of VEGF/CXCR4-
induced mobilization of Flk-1+/Sca-1+ cells and inhibition of VEGF-induced Akt 
and eNOS phosphorylation - a constellation of changes impinging on vascular 
function and repair. 
Our results also indicated that the bone marrow could be a specific locus of 
acrolein action. We found that acrolein inhalation increases accumulation of 
protein-acrolein adducts in the plasma and the bone marrow, suggesting that 
despite its high reactivity and rapid metabolism, acrolein was delivered from the 
lung into the systemic circulation and to distal vascular sites. Our previous 
studies have shown that exposure to tobacco smoke or acrolein resulted in the 
formation of protein-acrolein adducts in non-pulmonary sites 153,160. Thus, 
acrolein appeared to cross from the lungs and directly induce bone marrow 
toxicity. 
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Although acrolein inhalation decreased levels of circulating Flk-1 + /Sca-1 + 
cells, it increased the number of bone marrow-derived Flk-1+/Sca-1+ cells that 
accumulated acLDL and were positive for Ulex lectin binding in culture. Because 
the number of cells that grow out of the bone marrow on fibronectin-coated 
dishes is indicative of their population in the bone marrow 159, it appeared likely 
that exposure to acrolein increased proliferation of Flk-1+/Sca-1+cells in the bone 
marrow, while preventing their egress into the circulation. Alternatively, 
decreased mobilization by acrolein could indirectly result in the expansion of the 
bone marrow population of these cells. Nevertheless, this increase in levels of 
Flk-1+/Sca-1+ cells in the bone marrow indicated that acute acrolein exposure did 
not permanently impair the growth or viability of these cells but that it prevented 
their mobilization from the bone marrow. We suggest that this defect could be 
due to alterations in VEGF/SDF-1 signaling, but it also may be related to other 
specific processes such as cell release from the bone marrow stroma by matrix 
metalloproteases (MMPs), which is a NO-dependent process. Indeed, our 
measurements showed that exposure to acrolein is associated with a decreased 
level of active MMP-9 (73 kDa) in bone marrow lysate (Fig. Be). 
Depletion of Flk-1 + /Sca-1 + cells in the peripheral blood in acrolein-exposed 
mice could also be due induction of cell death. Our measurements showed that 
even brief exposure (2h) to acrolein resulted in a significant increase in the 
markers of cell death within the circulating Flk-1 + /Sca-1 + but not the Sca-1 + cell 
population (Fig. 4). These observations reinforce the view that the Flk-1+/Sca-1+ 
population is uniquely sensitive to acrolein; however, perSistent suppression of 
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the steady-state levels of circulating Flk-1+/Sca-1+ cells (Fig. 4) implies that the 
primary defect was in the bone marrow because the depletion of these cells, due 
to increased cell death or increased recruitment to sites of injury, was not 
adequately compensated via mobilization from the bone marrow. 
Because acrolein is one of the most reactive and toxic components of 
tobacco smoke, it is not surprising that many effects we observed with acrolein 
inhalation are consistent with findings of tobacco smoke exposure. Our 
observation that acrolein induced endothelial injury was consistent with evidence 
showing that exposure to combustion products generated by automobile 
exhaust 148 or tobacco smoke 146, 147 impairs endothelial function. Previous studies 
show that chronic smoking decreases the number of endothelial progenitor cells 
(EPCs) and that smoking cessation restores EPC levels in human subjects 161. 
The reversible effects of smoking are similar to the reversible effects of acrolein 
inhalation (see Fig. 4F), as well as particulate matter (PM2.S) exposure31 . In 
contrast to chronic smoking, brief exposure to secondhand smoke increases 
EPC levels162. Although we studied low-dose (O.5ppm) and brief (2h) exposures, 
we did not observe an increase in Flk-1+/Sca-1+ cells in acrolein-exposed mice. 
We speculate that the increase in EPCs upon brief exposure to secondhand 
smoke may be related to other combustion products such as C0163, which by 
inducing transient or pseudo-hypoxia could increase EPC mobilization. Yet, 
inhibition of VEGF signaling by secondhand smoke exposure 164 is similar to the 
effect of acrolein (Fig. 9) indicating that some of the pathological effects of 
secondhand smoke could be mediated by acrolein. 
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The levels of acrolein used in the current mouse exposure studies are 
relevant to those encountered by passive and active smokers as well as humans 
with occupations that include high level or chronic exposure to vehicle exhaust or 
smoke (e.g., bus drivers, bartenders, firefighters). Given the obvious lack of 
systemic toxicity (Tables 5 and 7) in mice, our observations suggested that 
acrolein at environmentally relevant levels could suppress circulating Flk-1 +/Sca-
1+ cell numbers without inducing overt toxicity. Moreover, it is important to point 
out that humans are exposed to acrolein not only from combustion, but also from 
foods and beverages, which contain high levels of acrolein 165. In addition, 
acrolein is generated endogenously during lipid peroxidation and via 
myeloperoxidase activity at sites of inflammation 166. Hence acrolein generated 
endogenously from distal inflamed tissues could also suppress Flk-1+/Sca-1+ cell 
mobilization from bone marrow (and other Sites) and decrease the circulating 
levels of these cells. Nevertheless, the pathophysiological significance of 
acrolein-induced changes in Flk-1 + /Sca-1 + cells remains unclear and deserves 
additional assessment. Previous studies show that the circulating levels of these 
cells are increased acutely in response to injury and that chronic suppression of 
similar progenitor cells is associated with an elevated CVD risk in humans 17. In 
our analyses, we measured considerable antigenic diversity within the Flk-
1 +/Sca-1 + population, which has characteristics of monocytes, T- and 8-cells. 
However, most of these cells were CXCR4+ (Fig. 3C) and they were mobilized by 
VEGF/AMD3100 which indicated that this population was likely to be recruited to 
the site of hypoxic or traumatic tissue injury. Moreover, the cells were also Id 1 + 
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(Fig.2E). Recent work suggests that Id1 is a selective marker of EPCs because 
ablation of 1d1 in bone marrow-derived cells reduces circulating EPC levels and 
induces significant defects in angiogenesis as Id1 + cells are incorporated in 
tumor neo-vessels167. Thus, the Flk-1/Sca-1 population affected by acrolein 
could be important for wound healing and angiogenesis. 
Wound healing is a complex process. It involves the clearance of cell 
debris, regeneration of injured tissue, and the growth of new blood vessels. This 
process requires the recruitment of a diverse set of progenitor cells containing 
both monocytic 168 and endothelial167 characteristics, which ultimately turn into 
macrophages and vascular cells to secrete proteases, cytokines and growth 
factors that promote growth of tissue-resident cells. Therefore, we speculate that 
suppression of this recruitable and pro-angiogenic cell population by acrolein 
could lead to deficits in wound healing capacity. Future work is required to 
identify the effects of acrolein on specific cell populations and how these interfere 
with individual steps in the wound healing response. 
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CHAPTER III 
EFFECTS OF ACROLEIN ON ANGIOGENESIS 
Introduction 
Angiogenesis and vasculogenesis are two processes responsible for 
vascular development in both adults and fetal gestation 169. The process of 
angiogenesis is the development of new vessels from preexisting vessels, while 
vasculogenesis refers to the development of a primitive vessel frame work by 
stem and progenitor cells 170. Angiogenesis is highly regulated and controlled by a 
balance of stimulators (e.g. vascular endothelial growth factor, angiopoetin-1, 
and erythropoietin) and inhibitors (e.g. angiostatin, platelet factor 4, interferon-I') 
of vascular formation 171. In ischemic diseases, both hypoxia and inflammation 
are fundamental for the stimulation of angiogenesis 172. Several disease states 
such as Alzheimer's 173, coronary artery disease 174, arthrosclerosis 175, and 
diabetes 176 have decreased angiogenesis and wound healing ability. Diabetics 
often suffer from a plethora of angiogenic-related health issues retinopathy 177, 
neuropathy178, nephropathy179, which can lead to ischemic ulcers and gangrene. 
Aside from diabetes, active and passive smokers are subject to increased 
cardiovascular health risks brought on by decreased angiogenesis 180. Studies 
have shown smokers do not respond to ischemic injury or stimuli as do healthy 
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non-smokers 181. Cigarette smoke exposure has been shown to decrease 
angiogenesis, both in vivo and in vitro182. The chemical(s) found in cigarette-
smoke that affect angiogenesis in active smokers and those exposed to second 
hand smoke are yet to be identified. Angiogenesis was thought to develop solely 
from the sprouting of local endothelial cells, however, the discovery of endothelial 
progenitor cells (EPCs) revolutionized this dogma78. EPCs are vital for ongoing 
endothelial repair of damaged vessels 136. Circulating EPCs incorporate into the 
sites of neovascularization and injury, improving endothelial function 183. Previous 
studies have also shown active smokers have decreased numbers of circulating 
EPCs 184,185, which can account for decreased angiogenesis and cardiovascular 
health seen in smokers 185. EPCs are positively correlated with wound healing 
and angiogenic ability186. Studies from our lab, presented in chapter II of this 
thesis show EPCs (Flk-1+/Sca-1+) are decreased in a time and dose dependent 
manner when mice were exposed to acrolein, much like the phenomenon seen in 
chronic smokers 187. 
In this study we hypothesized that exposure to acrolein could prevent 
angiogenesis by preventing ischemic injury-induced mobilization of EPCs. 
Methods 
All Experimental procedures and protocols were reviewed and approved by the 
Institutional Animal Care and Use Committee of the University of Louisville, and 
conform to the NIH "Guide for the Care and Use of Laboratory Animals". 
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Tube forming assay 
Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in endothelial 
basal media (Clonetics/Lonza) supplemented with 20 % FBS (Invitrogen), human 
endothelial growth factor (hEGF), hydrocortisone, gentamycin/amphotericin B 
(GA) and bovine brain extract (BBE; SingleQuot®, Clonetics/Lonza) under 
standard cell culture conditions (3rC, 5 % CO2). Cells were grown in 10cm 
dishes until 80 % confluent. Cells were treated with 0, 2.5, or 5mM acrolein in 
5mL of Hanks Buffering solution (HBSS+) supplemented with 5IJM glucose for 
30min (3rC, 5 % CO2), while controls were incubated in 5mL of HBSS+ alone. 
Cells were washed with warm HBSS+ and allowed to recover for 4h in fresh 
media (3rC, 5 % CO2). Cell were then trypsinized and seeded in a 96 well plate 
(1X104 cell/well) coated with Matrigel® (BD Biosciences). Pictures were taken 
every 30min of tube formation and counted for 6h using Evos® microscope. 
Acrolein inhalation 
Acrolein atmospheres were generated from a liquid refillable humidification tube 
(LFH, Kin Tek Laboratories, La Marque, TX, USA). Acrolein emission rate of the 
permeability tube was controlled by temperature, 1 ppm acrolein levels were 
produced by placing tube in a hot water bath at a set temperature of 50°C. 
Immersion of the permeability tube in the inert gas Nitrogen allowed for trace 
element of the acrolein to be emitted with high dosage accuracy. During 
exposure, acrolein concentration was continuously monitored using an in-line 
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photo ionization detector (ppb RAE+, Rae Industries, Sunnyvale, CA, USA) 
upstream of the cage insert vapor delivery unit (Teague Enterprises, Inc.) 
mounted on a standard polycarbonate rat cage (41 cm x 34 cm x 21 cm; :::::31L). 
Air or acrolein was distributed through a fine mesh screen at 3 Ipm by delivery 
units with a cyclone-type top that distributed air within 10% of the mean 
concentration at six locations in the cage (Scheme 6). Exposure cages were 
placed partially over heating pads (:::::22 °C) to allow mice to select preferable 
temperature. Mice were exposed to 1 ppm acrolein for 4 days 6h/d 
(99S.7±1.4ppb of) prior to induction of hindlimb ischemia (HLI) or to 2 ppm 
acrolein for 4 days (2138±S.4 ppb) prior to HLI. Acrolein inhalation was continued 
the day after induction of HLI in all study groups and perfusion recovery was 









Male CS7/BL6 mice at 12 weeks of age (Jackson Laboratories) were 
anesthetized with Isoflurane 1-3 % in 100 % oxygen at 1 mLl minute. Mice were 
shaved 24h before punch wounds were induced dorsally. A double punch wound 
was made on the back between the shoulder blades using a Smm punch skin 
biopsy pin (Integra Miltex Inc, York, PA, USA). (Fig. 10A) 
102 
Figure 10 
Figure. 10 punch wound model representative picture of 5mm punch wound 
location 
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Hind limb ischemia 
Male C57/BL6 mice at 12 weeks of age (Jackson Laboratories) were 
anesthetized with isoflurane 1-3 % in 100 % oxygen at 1 mLl minute. Mice were 
shaved and then sensitive skin Nair (Church & Dwight Co.,Princton, NJ, USA) 
applied to remove all hair on the lower limbs 24h before surgery (Fig. 11A). Mice 
were anesthetized with isoflurane 1-3 % in 100 % oxygen at 1 mLl minute, the 
femoral artery was ligated distal of the femoral bifurcation and proximal to the 
ankle joint using 7-0 silk suture (Johnson & Johnson Co., Ethicon, Cornelia, GA, 
USA), approximately 1 cm of femoral artery was excised between the ligation 
pOints (Fig.12B). Skin was closed using 5-0 polyethyl (Ethicon) discontinuous 
suture. Mice were given 0.05 mg/kg of buprenorphine for pain management 1 
hour before surgery. Mice were allowed to recover for 24h before starting 
acrolein inhalation. Mice were euthanized and changes in EPC levels were 
measured after surgery by flow cytometry (see Chapter 2). Perfusion recovery 











Figure 11. Representative pictures A, shows transverse abdominal line and area 
shaved then depilatory cream used for hair removal before HLI surgery, e, 
shows a representation of the HLI surgery and excision of the femoral artery and 
ligation points. 
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Laser Doppler perfusion imaging 
Blood perfusion in the ischemic (right) and normal (left) hind limb was measured 
with laser Doppler perfusion imaging (LDPI) system (PIMII, Perimed Instruments, 
North Royalton, OH). Low or no blood perfusions were displayed in dark blue, 
and the highest perfusion intervals were displayed in red. When laser light 
penetrates the tissue under study it is scattered or partly absorbed. Some of the 
scattered light returns to the tissue surface, where it is registered by a photo 
detector inside the instrument head. Information sent back to the instrument head 
which is read by the machine and provides information about the microcirulatory 
blood flow. According to the Doppler principle, light particles which hit moving 
blood cells undergo a change in wavelength/frequency otherwise known as 
Doppler shift. The perfusion can be calculated because the magnitude and 
frequency distribution of the Doppler shifted light are directly related to the 
number and velocity of blood cells but unrelated to their direction of movement. 
Perfusion data was shown as mean perfusion in volts. Mice were placed at a 
depth of 12cm from the head of the PIM II on a black non-reflectant surface. The 
laser was allowed to warm up for 15-20min before use. The machine was set on 
high resolution, with a set threshold voltage of 6. Analysis of hind limb ischemia 
data compared ischemic to non-ischemic limbs and subtraction of average 
background voltage from each captured image. Data was presented as the 
perfusion ratio ischemic to non-ischemic limb. 
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Complete blood count 
After select exposures, 100 1-/1 of blood were used for complete blood count 
analysis (CBC; Hemavet 500, Coulter Counter, Oxford, CT). 
Histology 
Animals were anesthesized (pentobarbital; 40mg/kg). Whole thigh muscle 
including adductor longus, gracilis, adductor magnus and biceps femoris of both 
legs were harvested (Fig 12A-I). The gastronemius muscles were also harvested 
from both ischemic and non-ischemic limbs and fixed in 10 % neutral buffered 
formalin (NBF) for 24h. Fixed tissue was paraffin-embedded and cut into 51-/M 
thick sections and placed on slides. Sections were stained with UE-Lectin-FITC 
(1 :50; Vector Laboratories, Burlingame, CA, USA) and anti-a-Smooth Muscle 
Actin-FITC (1 :250; Sigma) antibody for 1 hat 37°C. Slides were washed and 
nuclei were stained with DAPI (Molecular Probes, Invitrogen, Carlsbad, CA, 
USA). Auto-fluorescence was quenched with 0.1 % Sudan black solution for 30 
min at RT. Slides were again washed under running distilled water and cover 
slipped using Slow Fade® Gold anti-fade mounting reagent (Invitrogen). Capillary 
densities were calculated as the area of vessels positive for FITC-Lectin within 
each field. Arteriogenesis was calculated by counting the total number of a-SMA 
positive vessels within each field. Slides were examined by fluorescent 
microscopy (Evos microscope 20X) in four different random fields for capillary 
area calculations, while seven random fields were taken for a-SMA positive 
vessels. Pictures were analyzed using Nikon Elements software. 
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Figure 12 
Figure 12. Representative pictures of A-I, removal of ischemic and non-ischemic 




Tube forming assay 
To examine the effects acrolein has on angiogenesis, we first studied its 
effects on the spontaneous tube formation by endothelial cells. For this, HUVECs 
were cultured to 80% confluency, then treated with HBSS+, 2.5 or 5IJM of 
acrolein in HBSS+ for 30min. Acrolein decreased tube formation at both 2.5 and 
5IJM concentrations (Fig.13A-B). However, 2.51JM acrolein treated HUVECs 
recovered to that of control by the 6h time point, while the tube formation 
plateaued at 3h and never recovered after 5IJM acrolein treatment (Fig.13A-B), 
showing that acrolein can affect the angiogenic ability of endothelial cells. 
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Figure 13 
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Figure 13. Model of in vitro angiogenesis. A, Representative images of in vitro 
tube formation after treatment with acrolein 0, 2.5, or 5IJM for 30min. B, 
Quantification of tube formation following acrolein incubations. Data are 
mean±SEM (n=3/group). * p<0.05 vs. control. 
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Ischemic injury recovery 
Ischemic injury has been shown to mobilize EPCs and play an intricate 
part in wound healing and neovascularization of injured tissue 136. Our studies 
have shown that acrolein decreases circulating EPCs but increases proliferation 
within the bone marrow187. Any changes in mobilization of EPCs due to acrolein 
inhalation will be more apparent when EPC levels peak within the circulation after 
induction of HLI. To determine peak EPC mobilization after ischemic injury, we 
performed a time course study. EPCs were measured in mice without HLI, and at 
2,4,8, and 12 (n=4) days after the induction of HLI. EPC levels in circulation 
peaked 2 days after hindlimb ischemia, then returned baseline levels by day 12 
(Fig.14B). To determine the effect acrolein has on mobilization of EPCs in 
response to ischemic injury, mice were exposed to 1 ppm acrolein inhalation 4 
days pre-surgery and continued acrolein inhalation 2 days post-surgery (Scheme 
7). Peripheral blood was drawn and flow cytometry analysis performed to 
determine circulating EPC levels. EPCs were gated as previously described, Flk-
1 +/Sca-1 + cells were gated out and plotted for CXCR4 positivity (Fig.14A). 
Acrolein did not affect circulating Sca-1+/CXCR4+ cell number (Fig. 14C). 
However, acrolein did decrease Flk-1+/Sca-1+/CXCR4+ cells within the circulation 
(n=6,6; air 4.7±O.8 cells/IJL; acrolein 2.9±1 cells/IJL; p<O.05; n=6,6; Fig. 140). To 
determine whether EPCs are in an increased proliferative state within the bone 
marrow, we examined cell cycle of Flk-1+/Sca-1+ cells and found no difference 
between cell cycle or total cell numbers (Fig. 14E). Stem, T-and 8-cells that 
mobilized were measured to determine if any subset of Flk-1 + /Sca-1 + EPCs were 
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affected. A subset within the Flk-1+/Sca-1+ cell population, CD31+/B220tCD8-
/CD19+/CD3+ cells were increased in acrolein-exposed mice compared with air 
(air O.05%±O.005; acrolein O.08%±O.005; p<O.05; n=6,6; Fig. 14E-G). The stem 
cell panel showed that two different subsets of Flk+/Sca+ cells were decreased in 
acrolein-exposed mice compared with air; subset 1 B220+/CD31+/CD11b-
,CD115-/CD19+ (air O.08±O.002%; acrolein O.05±O.001 %; n= 6,6; p<O.05; n= 6,6; 
Fig. 14H-I) subset 2 B220+/CD31 +/CD11 b-,CD115-/CD19- (air O.09±O.001; 
acrolein O.04±O.001; n=6; p<O.05; n=6,6; Fig. 14H-I). 
External wound healing and EPC response to ischemic injury is hampered 
in smokers but is reversible with cessation of smoking 188. To further elucidate if 
acrolein had any effect on superficial wound healing like what is seen in smokers, 
double 5mm punch wound technique was employed. A short 2 day punch model 
was used to test if acrolein inhalation affected mobilization of EPC in response to 
the injury (Scheme 7). Circulating EPC levels in the punch wound model was not 
significant between air-exposed and acrolein-exposed mice (Fig.1SA-D). 
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Scheme 7 Two day hindlimb ischemia treatment protocol 
End 
Days I 1 2 3 I 4 I surgery I 6 7 I , J 
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Figure 14. Two day mouse model of hindlimb ischemia and characterization 
and A, representative dot plots of gated FSC and PE-CXCR4 fluorescence of 
Flk-1+/Sca-1+ cells that are also CXCR4 positive from air- and acrolein- treated 
mice. B, Quantification of time course EPC levels per IJL after the induction of 
hindlimb ischemia, measurements taken from baseline, days 2, 4, 8 and 12 from 
whole blood. C, Quantification of CXCR4+/Sca-1 + cells from 2 day hindlimb 
ischemia after 1 ppm acrolein inhalation from whole peripherial blood. 0, 
Quantification of Flk-1+/Sca-1+/CXCR4+ cells 2 days after hindlimb ischemia and 
1 ppm acrolein inhalation from whole blood. E, Quantification of cell cycle from 
bone marrow Flk-1+/Sca-1+ cells of 2 day 1ppm acrolein hindlimb ischemia mice. 
F, representative dot plots of gated FSC and gated T-cell and B-cell markers. G, 
Characterization of Flk-1+/Sca-1+ cell using T and B-cell markers after 2 days of 
hindlimb ischemia and 1 ppm acrolein exposure. H, representative dot plots of 
gated FSC and Stem cell markers I, Characterization of Flk-1+/Sca-1+ cell using 
stem cell markers after 2 days of hindlimb ischemia and 1 ppm acrolein exposure. 
Data are mean±SEM (n=4-6/group). * p<O.05 vs. control. 
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In order to determine if acrolein could affect wound closure we examined 
the progression of wound healing. Double 5mm punch wounds were induced 
dorsally and followed until 90% closure (Scheme 8). Wound closure of acrolein-
exposed mice was not significantly different when compared to air controls, in 
both groups there was 90% wound closure within 10 days (Fig.15E-G). 
To further determine acroleins effect on ischemia induced EPC 
mobilization, a more severe model of hindlimb ischemia was employed. Mice 
were exposed to 1 ppm acrolein for 4 days prior to HLI surgery. After surgery 
profusion recovery was followed and laser Doppler profusion images were taken 
of ischemic and non-ischemic limbs on days 0, 8, 12, and 18 (Scheme 9). There 
was no significance between profusion recovery of acrolein-exposed mice when 
compared to air-exposed mice (Fig. 16A-B). Circulating EPC levels were 
compared on day 20 of HLI, Sca-1+/CXCR4+ cells and Flk-1+/Sca-1+/CXCR4+ 
cells were not significant when compared with air-exposed mice (Fig. 16C-D). 
For further confirmation and analysis of angiogenesis thigh and Gastronemius 
muscles of both ischemic and non-ischemic legs were harvested and stained for 
immunofluorescence. Tissue sections were stained for UE-Lectin to detect 
capillary density and a-smooth muscle actin (a-SMA) in order to detect arterioles 
(Fig. 16E). Quantification of capillary density and total number of a-SMA positive 
vessels showed there were no changes in angiogenesis after hindlimb ischemia 
between acrolein- and air-exposed mice (Fig. 16F-G). 
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Scheme 8 Two day punch wound model treatment protocol 
End 
Days I 1 2 3 4 I 5mm ptlldJ 6 7 I 
I , 
1 ppm acrolein 1 ppm acrolein 
Scheme 9 Ten day punch wound treatment protocol 
End 
Days I 1 I 2 3 I 4 I ; I 6 7 I 8 I 9 I 10 I 11 I 12 I 13 1 14 1 151 
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Figure 15. Punch wound mouse model. A, Quantification of CXCR4+/Sca-1+ 
cells from 2 day punch wound model after 1 ppm acrolein inhalation from whole 
peripheral blood. B, Quantification of Flk-1+/Sca-1+/CXCR4+ cells after 2 days 
punch wound model after 1 ppm acrolein inhalation from whole blood. C, 
Quantification of CXCR4+/Sca-1+ cells from 10 day punch wound model after 
1 ppm acrolein inhalation from whole peripheral blood 0, Quantification of 
CXCR4+/Sca-1+ cells from 10 day punch wound model after 1ppm acrolein 
inhalation from whole peripheral blood E, Representative images of 5mm punch 
wound on day 0 and 8 F, Quantification of punch wound healing every 2 days 
until day 8. Data are mean±SEM (n=6/group). * p<0.05 vs. control. 
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Figure 16. Hindlimb ischemia perfusion recovery and acrolein 1 ppm 
inhalation. A, Representative laser Doppler measurements at days 0, 8, 12 and 
18. B, Quantification of laser Doppler perfusion ratios following hindlimb ischemia 
in control mice, or mice exposed to 1 ppm acrolein inhalation. C, Quantification of 
Sca+ cells from 20 day hindlimb ischemia model after 1 ppm acrolein inhalation 
from whole peripheral blood 0, Quantification of Flk-1 +/Sca-1 + cells from 20 
days of hindlimb ischemia and 1 ppm acrolein inhalation from whole peripherial 
blood. E, Representative photographs of thigh muscle from 20 day hindlimb 
ischemia mice and 1 ppm acrolein exposure, stained for UE-Lectin and arterioles. 
F, Quantification of capillary and, G, total a-SMA positive vessels. Data are 
mean±SEM (n=6/group). * p<0.05 vs. control. 
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HLI perfusion was followed for an extended time to determine the affect 
acrolein potentially has on angiogenesis in vivo. Higher concentrations of 
acrolein (2ppm) were used to determine if the effect is dose dependant (Scheme 
11). Acrolein mice did not have hampered leg reperfusion, both air- and acrolein-
exposed mice had 74-76% recovery of blood flow by day 10 post-surgery (Fig.17 
A-B). Circulating Sca-1+/CXCR4+ cells remained insignificant at this time point as 
well. Acrolein-exposed mice had significantly decreased levels of EPCs (Flk-
1 +/Sca-1+/CXCR4+) compared with air-exposed mice (air4.4±0.5; acrolein 
1.4±0.3; n=6,6; p<0.05; Fig. 17 C-D). Complete blood counts of acrolein-exposed 
mice were decreased after induction of HLI in both 1 ppm/2d acrolein inhalations 
and 2ppm/10d acrolein inhalations (Table 11). 
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Scheme 11 Ten day hindlimb ischemia treatment protocol 
End 
Days I 1 1 2 3 1 4 1 $OrnerY 1 6 7 1 8 1 9 1 10 1 11 1 12 1 13 1 14 1 151 
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Figure 17. Hindlimb ischemia perfusion recovery of acrolein 2ppm 
inhalation mice. A, Representative laser Doppler measurements at days 0, 1,3, 
6, 10. B, Quantification of laser Doppler perfusion ratios following hindlimb 
ischemia in control mice, or mice exposed to 2ppm acrolein inhalation. C, 
Quantification of Sca-1 + cells from 10 day hindlimb ischemia model after 2ppm 
acrolein inhalation from whole peripheral blood 0, Quantification of Flk-1+/Sca-1+ 





Blood parameters in C57BU6 mice exposed to air or acrolein with HU 
Control no HLI 20HLI 20DHLI 10DHLI 
Air Air Acrolein. 1ppm Air Acrolein, 1ppm Air Acrolein.2ppm 
WBC· 237O:t585 3832±399 2173±178' 2l00±320 l663±172 3363±376 1676±334' 
NEe 362±64 744±93 400±34+ 334.:!:80 183.:!:23 686±55 313±4Z 
LY- 1942±518 2098±391 1708±173' 1668±246 1397±146 2528±330 1286±283' 
MO- 57±15 82±17 45±32' 74±17 78±11 141±24 73±1?" 
RBO 9035±298 n96±283 791S±199 n50±274 7996±274 8716±227 8418±224 
HCT(%) 42.2±12 33.9±13 343±O.9 34.8±O 4 35.9±1.1 37.38±10 36.S±1l 
Ht>c 11.1±O.3 11 4±O 5 118±0.3 11.6±O2 11 7±O.4 12.15±0.3 12.0±0.3 
PLTo 835±50 S79±35 S09±25 565±17 569±21 783±53 652±32 
MCV" 46.9±O.3 43.8±O2 43.7±O 2 449±0.4 44.8±0.3 42.9±0.6 43.4±02 
MCH" 122 ±O.1 14.7±O2 14.9±O2 14.9±02 14.6±0.1 13.9±02 14.2±0.1 
MCHCc 26.1±O1 33.4±O.3 34.1±O.4 332±02 32.6±0.3 32.5±0.3 32.8±32.3 
RDW(%) 17.3±O.5 16.8±O2 16.1±O.3 17.1±O.3 170±O2 17.5±0.3 17.3±02 
MPVd 38±Q l 41+003 41+003 40+0 03 !llliO.03 43+006 41+0.1 
Male, 12-14 week old mice were exposed to air or acrolein (1 or 6hlday) for 4 days, with or without HU, n-6 per group. Mice were 
euthanized immediately after exposure. Units a =(Klml). b =(Mlml). c =(gldL) , d =(nglmlJ; Values are mean ± SEM; * p <0.05 vs. air-
matched group; n=8 micelgroup Abbr. WBC, white blood cell; NE, neutrophil; LY,lymphocyte; MO, monocytes, RBC, red blood cell; 
HCT, hematocrit; I::fb. hemoglobin; PL T, platelet; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin: MCHC, mean 
corpuscular hemoglobin concentration, RDW. red cell distribution width, MPV, mean platelet volume. p<0.05, One-Way ANOVA; compared 
to there prospective air groups 
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Discussion 
In the present study, we show that acrolein treatment decreases 
spontaneous tube formation of HUVECs in vitro and acrolein inhalation 
decreases mobilization of EPCs in response to ischemic injury. 
Previous studies have shown that exposure to cigarette smoke decreases 
circulating EPCs and decreases angiogenic recovery after induction HLl189. 
Acrolein inhalations that were performed are pure exposures to acrolein, 
compared to the plethora of chemicals contained in cigarette smoke, so there 
cannot be a direct comparison between the results of these two studies. 
However, acrolein is a highly reactive component found within cigarette smoke 
and is a likely candidate for the development of vascular pathologies seen in 
smokers. Indeed, in this present study we report a decrease in tube formation by 
HUVECs treated with acrolein for 30min. 
Angiogenesis and neovascularization are complex biologic responses and 
are important processes in ischemic injury and disease 190. In both post-natal 
physiological and pathological neovascularization bone marrow-EPCs play an 
essential role 191. Studies have shown HLI causes mobilization of EPCs from 
bone marrow to the site of ischemic injury, mobilization of EPCs is essential for 
profusion recovery and limb salvage 192. Ischemic injury is a strong stimulus for 
increased release of VEGF, which is a potent EPC mObilizer193. In an attempt to 
elucidate if acrolein affects mobilization of EPCs in response to ischemic injury, 
mice were exposed to 1 ppm acrolein for 4 days before HLI surgery and 
euthanized at the peak of EPC mobilization 2 days post-surgery. Circulating 
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EPCs were significantly decreased in acrolein-exposed mice, confirming a 
blunted response to ischemic stimuli. Previous data have shown acrolein-
exposed mice have a hampered mobilization to VEGF-injections. These results 
support the conclusion that EPCs are not responding to endogenous VEGF level 
increases that occur after ischemic injury and thus do not mobilize 187. However, 
the precise mechanism responsible for this blunted response and mobilization 
remains to be elucidated. 
Circulating EPC levels have been positively correlated to cardiovascular 
health and increased angiogenesis with improved ischemic recovery 136. We 
further investigated the decrease of circulating EPC levels and if the decrease 
would affect ischemic recovery of HLI. Serial Doppler imaging showed perfusion 
recovery was not affected in any HLI model; at 1 ppm 20 day post-HLI nor the 
2ppm 10 day post-HLI model. 
In conclusion, acrolein does affect EPC mobilization in response to 
ischemic injury. However, angiogenesis and reperfusion does not seem to be 
affected by acrolein inhalations. Despite the negative results reported here, 
acrolein could still affect angiogenic recovery after induction of HLI. The question 
remains open and further research and technique development is needed to 





Studies presented here were designed to develop an understanding of 
how acrolein, a byproduct of environmental pollutants, affects vascular health by 
altering the recruitment and mobilization of endothelial progenitor cells (EPCs). 
My thesis is that EPCs are sensitive targets for environmental insults, such 
as acrolein, thus increasing the risk of developing cardiovascular disease 
and endothelial dysfunction. Studies described here show that exposure to 
acrolein by inhalation (Aim 1), prevents mobilization of EPCs by cytokine 
stimulation (Aim 2). These studies also, evaluated perfusion recovery after 
hindlimb ischemia in mice exposed to acrolein inhalation (Aim 3). 
Results of the first set of experiments (Chapter II), show that inhaled acrolein 
preferentially suppresses circulating endothelial progenitor cells (EPCs). Acrolein 
specifically decreases this cell population without affecting the level of Sca-1+ 
cells, indicating a unique sensitivity of the EPC population to acrolein. The effects 
of acrolein on this population were, however, transient, and recovery in acrolein-
free environment for 7 days led to a return of circulating EPCs to baseline levels. 
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The decrease in circulating levels of EPCs appears to be the result of a defect 
in mobilization. Acrolein selectively suppressed basal levels of EPCs but not the 
Sca-1+ cell pool indicating that it preferentially affects VEGFR-2-expressing cells. 
In support of this conclusion, we found that acrolein exposure in vivo blocked 
VEGF-induced phosphorylation of Akt and eNOS in isolated aorta ex vivo. The 
prevention of EPC mobilization was also associated with decreased plasma NOx 
levels as well, suggesting that some of the effects of acrolein on EPC 
mobilization could be attributed in part to a decrease in NO production or 
bioavailablity. 
We also found that acrolein inhalation was associated with the accumulation 
of protein-acrolein adducts in the plasma and bone marrow. This observation 
suggests that despite its high reactivity, acrolein is delivered from the lung into 
the systemic circulation and to distal vascular sites. Thus, acrolein appears to 
cross from the lungs and directly stimulate bone marrow EPCs. Indeed, our 
studies showed that bone marrow derived cells (SMOC) from acrolein-exposed 
mice were more proliferative when cultured on fibronectin-coated plates. 
Enhanced SMOC proliferation was observed as early as 1-2 days during initial 
colony formation, which contain clusters that stained for Flk-1 +/Sca-1 + as well as 
positive for acLOL uptake and Ulex lectin binding. The apparent increase in 
proliferation and a decrease in circulating EPC levels indicate that acrolein does 
not impair the growth or viability of these cells, but that it prevents their 
mobilization from the bone marrow. We suggest that this defect may be due to 
alterations in VEGF/ CXCR4 signaling but could also be related to other 
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processes such as cell release from the bone marrow stroma. The specific 
mechanism by which acrolein enhances BMOC proliferation but inhibits their 
mobilization remains unknown and needs further investigation. 
Because acrolein is one of the most reactive and toxic components of 
tobacco smoke, it is not surprising that many of the effects we observed with 
acrolein inhalation are consistent with tobacco smoke exposure. Our 
observations that acute high level acrolein slightly injures the murine endothelium 
are similar to reported effects of tobacco smoke on endothelial cells 194. The 
acrolein-induced suppression of NOx could be related to diminished levels of 
EPCs because both parameters returned to baseline levels following a 7 -day 
recovery period. Moreover, we found that exposure to 1 ppm acrolein for 4 days 
did not induce frank endothelial dysfunction although the levels of EPCs were 
decreased, suggesting that decreases in the circulating EPC levels precede 
endothelial dysfunction. 
Humans are exposed to acrolein not only from tobacco smoke and air 
pollution, but also to acrolein present in foods and beverages 165. In addition, 
acrolein is generated endogenously during lipid peroxidation and 
myeloperoxidase activity at sites of inflammation 166. Our studies suggest that 
acrolein generated endogenously within the bone marrow or transported to the 
bone marrow from distal inflammatory processes could also suppress EPC 
mobilization and decrease circulating levels of EPCs by triggering mechanisms 
similar to those seen in animals exposed to inhaled acrolein. 
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In this project, we characterized and counted EPCs independent of CD45+ 
status because the majority (>90 %) of EPCs express CD45 antigen. We 
reasoned that because of acrolein's propensity for targeting the endothelium, 
acrolein exposure could result in injury and mobilization of EPCs for repair. 
Chronic smoking is associated with a decrease in EPC levels in humans similar 
to the suppression of EPCs in blood that we have reported 195. Hence, these 
finding suggest a novel connection between a specific component of cigarette 
smoke, acrolein, and air pollution generated from the combustion of organic 
materials and provide new insights into the mechanisms by which exposure to 
these pollutants can increase the risk of developing cardiovascular disease. 
We next wanted to determine the effects acrolein had on vascular 
regeneration using in vivo and ex vivo approaches. Our cell culture studies 
showed that acrolein treatment decreased spontaneous tube formation of 
HUVECs seeding on Mitragel. To further elucidate the effects acrolein on 
angiogenesis and profusion recovery we studied two models of wound healing, 
i.e. ,the punch model and hindlimb ischemia . However, we found that the 
progression of wound healing in these models was not affected by acrolein 
exposure-. We reasoned that the punch wound model is not a severe model of 
ischemia and does not elicit the hypoxic response necessary to significantly 
increase plasma VEGF and increase circulating EPC levels to the extent of HLI 
model196. Studies have shown VEGF exerts dominant functions during 
angiogenesis and is necessary for EPC mobilization from the bone marrow. 
Hindlimb ischemia is also a potent stimulator of VEGF release and mobilizes 
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EPCs into the circulation almost 13 fold over baseline 197. We found that with the 
induction of hindlimb ischemia, circulating EPC levels peak on day 2 of ischemic 
injury. However, after day 2 of HLI mice exposed to 1 ppm acrolein had 
significantly decreased circulating EPC levels. This data suggests exposure to 
acrolein prevents EPC mobilization due to hindlimb ischemia perhaps by 
preventing the stimulatory effects of endogenous VEGF on the mobilization of 
EPCs from the bone marrow in response to HLI. To develop these observations 
further, an extended 1 ppm acrolein exposure was carried out to determine if 
decreased circulating EPCs affected angiogenesis and reperfusion recovery after 
HLI . Our results showed that acrolein exposure did not affect circulating EPC 
levels or the rate of recovery of tissue perfusion. Hence, no determination could 
be made if EPCs affected perfusion recovery because EPC levels did not differ 
between control and inhalation animals. To examine whether the effects of 
acrolein on angiogenic recovery might be a dose-dependent phenomena, 
acrolein exposure levels were increased to 2ppm. Our results with the higher 
dose showed a trend towards decreased perfusion recovery of 2ppm acrolein-
exposed mice, however this did not reach statistical significance. Circulating 
EPCs were also not significantly different in HLI of 2ppm acrolein-exposed mice 
when compared with air-exposed mice. Both 1 ppm and 2ppm HLI studies 
produced negative results, however, in chapter III EPC levels were shown to 
return to baseline by day 12 of HLI. EPCs may become desensitized to 
mobilization stimuli after a period of time or EPCs mobilization could become 
exhausted after prolonged ischemic stimulation. Further research is needed to 
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determine the possible detrimental effects that acrolein could have on 
angiogenesis, vascular repair and how this could potentially effect wound 
healing. 
Overall, the data presented here support the global hypothesis that EPCs 
are a sensitive target for acrolein, thus increasing the risk for developing 
cardiovascular disease and endothelial dysfunction. 
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My research at the University of Louisville was initiated as an attempt to 
understand the link between environmental pollution and increased mortality 
rates. Previous studies have shown a strong negative correlation between 
pollution and developing heart disease, diabetes, and decreased wound healing 
ability, however the physiologic reason behind this still remains a mystery. In my 
research I studied adult endothelial progenitor cells (EPCs), a small subset of 
cells that have stem cell and endothelial cells properties and heal damaged 
endothelium. There is also a strong negative correlation between the number of 
circulating EPC and the risk for developing heart disease, diabetes, and 
decreased wound healing. Little has been done with the characterization of EPC 
in mice models, so our lab has done an extensive set of cell markers by flow 
cytometry and developing the first heirarchy of mouse EPCs. My main field of 
study came to be EPC and how they were affected by acrolein. Acrolein is a 
176 
highly reactive unsaturated aldehyde present in all forms of pollution in high 
amounts. In my research I have found acrolein inhalation does indeed decrease 
circulating endothelial cells and hinders angiogenic assays in vitro, in a time and 
dose dependant manner. With this knowledge our lab can now began to unravel 
the mystery behind pollution and high mortality rates, thus decreasing or even 
preventing pollution related deaths. 
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